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ABSTRACT 
Eukaryotic linear chromosomes face two problems that pose threats to genome 
integrity: (i) the end-protection problem, in which chromosome ends are recognized as 
double-stranded breaks by DNA damage responses, and (ii) the end-replication 
problem, in which loss of the chromosome extreme ends occurs in each cell division 
due to failure of DNA polymerases to replicate these termini.  The shelterin complex 
solves both the end-protection problem and regulates access of telomerase to solve the 
end-replication problem.  
Decreased telomerase activity in stem cells causes dyskeratosis congenita (DC), 
an inherited bone marrow failure syndrome characterized by telomere lengths <1st 
percentile. Accordingly, germline mutations in telomerase subunit genes (TERC and 
TERT) or telomerase biogenesis genes (DKC1, NOP10, NHP2, and WRAP53) are 
commonly associated with DC. Mutations in telomere biology genes (TINF2, CTC1, and 
RTEL1) are also observed in DC. However, in ~30 % of DC cases, the underlying 
genetic cause is unknown.  
TPP1, encoded by the ACD gene, is a component of the shelterin complex. Like 
other shelterin proteins, TPP1 protects the ends of chromosomes from illicit fusion 
events. In addition, TPP1 is uniquely responsible for recruiting telomerase to telomeres. 
A group of amino acids on the surface of TPP1, termed the TEL patch, is critical for 
telomerase recruitment and telomerase processivity. These functions of TPP1 make it 
an excellent candidate for harboring causative mutations of DC.  
Here, I report the identification of a single-amino acid deletion in the TEL patch 
and a missense mutation in the TIN2-binding domain of TPP1 in a patient suffering from 
a severe variant of DC, Hoyeraal-Hreidarsson syndrome. I further showed that the 
deletion abrogates both telomerase recruitment and enzymatic processivity, whereas 
the missense mutation does not have a significant effect on these functions.  The 
missense mutation, on the other hand, inhibits the interaction between TPP1 and TIN2, 
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another shelterin component responsible for recruitment of TPP1 to telomeres. 
Therefore, inhibition of this interaction may exert an indirect effect on the recruitment of 
telomerase to telomeres due to reduced TPP1. Thus, I propose that both the single-
amino acid deletion and the missense mutation contribute to the severe phenotype of 
the proband. 
In this study, I report the first instance of DC caused by a germline mutation in 
ACD, adding to the list of DC genes.  This study demonstrates for the first time that 
telomerase recruitment and processivity defect, caused by dysfunction of the TEL patch 
of TPP1 , results in secondary telomerase deficiency in DC. Thus, it reveals the critical  
role of TPP1 in  telomerase recruitment and processivity in stem cells.  Future animal 
models engineered to carry patient and TEL patch mutations will reveal the full extent of 
the contribution of the TEL patch to proper functioning of stem cells. 
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CHAPTER1: INTRODUCTION 
A. TELOMERES 
Eukaryotic chromosomes are linear. Although their linear structure confers 
certain advantages during evolution, chromosome ends have the potential to be 
mistakenly recognized as double-stranded breaks by the DNA repair machinery in cells. 
Thus, there must be a mechanism to protect natural chromosome ends from being 
recognized as DNA breaks. Well before the discovery of the double-helix structure of 
DNA, Hermann Muller (1938) and Barbara McClintock (1939) observed that the natural 
ends of linear chromosomes are protected from rearrangements and fusion events that 
often occur at internal regions in the chromosomes of fruit flies and of maize, 
respectively. Muller named these protected ends of chromosomes “telomeres”, which 
originates from the Greek word “telos” meaning end and “meros” meaning component. 
 In the following decades, it has become clear that chromosome ends have 
special properties and structures, including species-specific telomeric DNA repeats, 
telomere-associated proteins and specific terminal DNA end structures for telomere 
maintenance and end-protection. Our current-day definition of telomeres is that they are 
nucleoprotein complexes found at the end of all eukaryotic chromosomes. They are 
composed of telomeric DNA consisting of tandem GT-rich repeats and bound protein 
complexes. 
A.1. Telomeric DNA 
The telomeric DNA of most eukaryotes is composed of double-stranded short 
tandem DNA repeats followed by a G-rich 3’-overhang [4]. The sequence of these 
tandem repeats is dictated by telomerase, the ribonucleprotein complex responsible for 
telomeric repeat synthesis at telomeres. Telomerase is composed of a reverse 
transcriptase subunit (TERT) catalyzing telomeric DNA synthesis and an RNA subunit 
(TERC) serving as a template for DNA synthesis. Mammalian telomeres are comprised 
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of 5’- TTAGGG- 3’ with variable repeat numbers in different mammals [5],[6]. Laboratory 
mice have long, hypervariable telomere lengths, ranging from 30kb to 150 kb, whereas 
telomere length in humans is 10-15kb at birth [7-9].  
Telomeric DNA has been proposed to form a higher order structure, called a t-
loop, in which the telomere end folds back on itself and the 3’-overhang invades into the 
double-stranded DNA, forming a D-loop [10]. Recently, t-loop structures have been 
visualized at telomeres using super-resolution fluorescence imaging (STORM) in mouse 
splenocytes or in mouse embryonic fibroblasts (MEFs) [11]. Although the exact role of t-
loops in end protection is not known, the t-loop structure is thought to be involved in 
telomere protection of 3’ overhang via sequestration [12]. In addition to t-loop structures, 
due to its high G content, the single-stranded 3’ overhang can potentially form G-
quadruplexes. In humans, G-quadruplexes are thought to be important in telomere 
protection, suppression of recombination, and inhibition of accessibility of telomerase to 
telomeres [13]. 
A.2. The Shelterin Complex 
The linear nature of chromosomes causes two main problems for the cells: 1) 
How to protect the ends of chromosomes from degradation and fusion, the “end-
protection problem” and 2) How to replicate the extreme ends of the chromosomes, the 
“end-replication problem” (discussed below in section 2). 
The end-protection problem is defined by the inability of DNA-damage 
recognition and repair pathways to distinguish natural ends of chromosomes from 
damage-induced chromosomal double stranded breaks. Mammalian cells have two 
different signaling pathways that are activated by double-stranded breaks. While the 
ATM (Ataxia Telangiectasia Mutated) kinase signaling pathway is activated by double-
stranded DNA ends, the ATR (Ataxia Telangiectasia and Rad3 related) kinase pathway 
is activated by the single-stranded overhang DNA generated by trimming or resection of 
the 5’-end of double-stranded breaks. Activation of these pathways can lead to cell 
cycle arrest and cell death. Thus, it is important to keep these pathways repressed at 
telomeres in order to maintain genome stability and cell proliferation. Moreover, double-
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stranded breaks are repaired in cells either by homology-directed repair (HDR) or by the 
nonhomologous end joining (NHEJ) pathway, which can result in chromosome fusions. 
Therefore, cells also need to protect their chromosome ends from these repair 
pathways.  In summary, failure to distinguish natural chromosome ends from double-
stranded DNA breaks can result in cell cycle arrest (resulting from activation of ATM 
and/or ATR pathways), chromosome end-to-end fusions (resulting from activation of 
NHEJ), and sequence exchanges among telomeres or between telomeres and other 
regions of the genome (resulting from HDR activation) [14].  
The solution to the end protection problem in mammals is provided by the 
shelterin complex, which is composed of six known components: TRF1, TRF2, Rap1, 
TIN2, POT1 and TPP1 (Figure 1.1). Although shelterin, in general, functions in shielding 
the chromosome ends from being recognized as damaged DNA, each component of the 
shelterin complex has its own unique contribution to the protection of telomeres, as well 
as to telomere length maintenance [15], as discussed in following sections. 
TRF1  
TRF1, encoded by TERF1, was the first identified component of the shelterin 
complex. It specifically binds to TTAGGG repeats in double stranded telomeric DNA 
giving it the name TTAGGG repeat-binding factor 1 (TRF1)(Figure 1.1) [16]. The 
structure of TRF1 is divided into three domains; an acidic N-terminus, a central TRF 
homology (TRFH) domain and a C-terminal DNA-binding domain [17],[18].  
The acidic N-terminal domain differentiates TRF1 from TRF2. Through this 
domain, TRF1 binds to different accessory proteins. For instance, it harbors the 
RxxADG sequence that can bind to tankyrase 1 and tankyrase 2 [19]. Parsylation of 
TRF1 by tankyrases is proposed to open the shelterin complex, thereby enhancing 
telomerase-mediated telomere elongation [20, 21]. 
The C-terminal DNA binding domain is an approximately 50-amino acid long 
SANT/Myb-type region.  The SANT/Myb-type region is a structurally conserved DNA-
binding domain. Belonging to same protein family, the Myb and SANT domains are 
structurally similar; however, they are known to be divergent in their functions (i. e the 
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Myb domain binds to DNA but the SANT domain does not bind to DNA) [22, 23]. TRF1 
binds to DNA as a dimer, and dimerization is mediated by the central TRFH domain 
[24], [10]. Although TRF1 and TRF2 are structurally very similar, they recruit different 
sets of proteins to telomeres through their interactions. The TRFH domain of TRF1 
harbors a specific docking sequence recognized by the FxLxP motif of several specific 
accessory proteins. TRF1 binds to the FxLxP motif in the C-terminus of TIN2 [25, 26] 
The consensus DNA binding sequence of TRF1 was shown to be a half-site of 
5’-YTAGGGTTR-3’ by SELEX (systematic evolution of ligands by exponential 
enrichment) and interestingly, TRF1 can bind as a dimer to two distantly related half-
sites even in opposite directions [27]. From these studies, it was concluded that TRF1 
has a high spatial flexibility, presumably conferred by the flexible linker region. 
TRF1 is primarily implicated in telomere length maintenance in cells. In 
telomerase positive cells, it is a negative regulator of telomere length. Overexpression 
of TRF1 causes telomere shortening, whereas inhibition of TRF1 with a dominant 
negative form causes telomerase-dependent telomere elongation, presumably by 
affecting telomerase action [28-30].  In the mouse, TRF1 is indispensable. Targeted 
deletion of Terf1 in mice results in early embryonic lethality (at E5-E6). In this Terf1 -/- 
mouse, severe growth defects and apoptosis of the inner cell mass of blastocycts was 
detected. The embryonic lethality could only be briefly delayed by deletion of p53 [31]. 
Conditional deletion of Terf1 in mouse embryonic stem cells causes loss of TRF2 and 
TIN2 at telomeric ends, leading to telomere fusions with reduced telomere signal. These 
data indicate that TRF1 plays a key role in stabilizing telomere structure by interacting 
with other telomeric proteins [32]. Conditional deletion of Terf1 in stratified epithelial 
cells causes severe tissue degeneration due to telomeric damage, independent of 
telomere length maintenance [33]. In addition, TRF1 is suggested to prevent formation 
of fragile telomeres by contributing to efficient replication of telomeres [34], although its 
role in this process is currently unknown. 
 
TRF 2 
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TRF2, encoded by TERF2, is another double-stranded telomeric DNA binding 
protein present at mammalian telomeres (Figure 1.1). It was identified based on its 
shared SANT/Myc motif with TRF1 [18, 35]. In addition to the SANT/Myc domain, it also 
shares a central TRF homology (TRFH) domain with TRF1. These domains are 
connected by a flexible hinge domain, which is not structurally conserved between the 
two proteins [18, 27, 35, 36]. TRF1 and TRF2 also differ significantly in their N-terminal 
domain.  While TRF1 has an acidic N-terminal domain, TRF2 has a basic N-terminal 
domain containing a Gly/Arg-rich region, also referred to as a GAR domain [18]. 
The TRFH domain mediates the dimerization/ oligomerization of both TRF1 and 
TRF2. Both proteins bind to telomeric repeats as dimers but they cannot interact with 
each other due to differences in their TRFH domain. Interestingly, TRF2 has a tendency 
to be involved in higher order oligomerization, such as t-loop formation[37].  Although 
TRF2 is capable of mediating t-loop formation in vitro, it is not clear whether it has the 
same capability in vivo [10, 37]. Recently, Doksani et al. demonstrated direct evidence 
for the formation of t-loops and the requirement of TRF2 for the formation and 
maintenance of t-loops [11]. 
Differences in the TRFH domain of TRF1 and TRF2 result in recruitment of 
different sets of proteins to telomeres. Similar to TRF1, the TRFH domain of TRF2 also 
harbors a docking motif for binding its partners, but this motif is recognized by a 
different sequence, YxLxP, in accessory proteins. TRF2 binds to the YxLxP motifs of 
several accessory proteins, including Apollo (also known as Snm1b), XPF, Mre11, 
MCPH1 and PNUTs [25, 26].  TRF2 also interacts with Rap1 through its TRFH domain 
[38]. TRF2 also binds to a region in the N-terminus of TIN2 via its hinge region [26].   
TRF2 is primarily known for its role in telomere capping and end-protection. Like 
TRF1, deletion of Terf2 is not compatible with life in mice. Embryonic lethality occurs 
before E13.5 in Terf2-/- mice [39]. Because it is known that TIN2 and TRF1 both 
participate in stabilization of TRF2 at telomeres [40-42], the embryonic lethality of TRF1 
null and TIN2 null mice can also be explained by the loss of TRF2 at the telomeres. 
Conditional deletion of Terf2 in mouse embryonic fibroblasts (MEFs) showed 
senescence like-arrest in the presence of p53. In Terf2-/- p53-/- MEFs, genome-wide 
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telomeric fusions and DNA damage responses were detected, demonstrating the 
importance of TRF2 in telomere end-protection [39]. Expression of a dominant negative 
mutant of TRF2 also results in loss of telomeric overhangs due to either failure to 
protect the 3’ overhang from degradation or deficiency in generating new 3’ overhangs 
after replication. As a consequence of the loss of 3’ overhangs, telomere end-to-end 
fusions were generated through activation of the ATM/p53 DNA damage response 
pathway[43, 44]. TRF2 directly interacts with ATM, and removal of TRF2 from telomeres 
causes localization of phosphorylated ATM to the unprotected telomere ends to initiate 
an ATM-dependent damage response. Thus, TRF2 represses ATM-dependent damage 
responses by directly interacting with ATM [45, 46]. 
TRF2 is also important for  telomere length maintenance  by restricting the 
access of telomerase to telomeres via t-loop formation. Overexpression of TRF2 
induces telomere shortening, independent of the telomerase status of the cells [29, 44], 
and knocking down TRF2 leads to telomere elongation [47].  
Rap1 
The mammalian ortholog of Rap1 was identified as a TRF2-binding partner 
(Figure 1.1) [38]. Human Rap1 forms a complex with TRF2 through its RCT domain in a 
1:1 stoichiometry[48]. Although Rap1 has not been fully characterized, there are four 
distinguishable domains; an N-terminal BRCT domain, a single Myb domain, a coiled 
region, and a Rap1 carboxy-terminal (RCT) domain. The Myb domain is proposed to 
confer protein-protein interactions, whereas the RCT domain mediates the interaction of 
Rap1 with TRF2 in addition to homodimeric interactions. Additionally, there is a putative 
nuclear localization signal (NLS) in the C-terminus of Rap1[38]. 
The yeast counterpart of mammalian Rap1 is known to bind directly to telomeres 
through its two Myb domains. Despite the presence of a Myb domain, human Rap1 
requires TRF2 to bind telomeres. Recent ChIP analysis showed that Rap1 and TRF2 
have both distinct and overlapping binding sites on chromosomes. More specifically, 
although TRF2 recruits Rap1 to telomeres [39], Rap1 binds some extra-telomeric 
sequences that do not have consensus (TTAGGG)2 motifs, and this binding is thought 
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to be independent of TRF2 [49, 50]. Rap1 is proposed to form complexes with other 
factors thought to be involved in its extra-telomeric functions, including subtelomeric 
gene silencing and transcriptional regulation [49]. 
Rap1 is also implicated in telomere length regulation.  Based on deletion 
mapping studies, the BRCT and Myb domains are proposed to recruit one or more 
putative accessory factors that play a role in the negative regulation  of telomere length. 
In addition, deletion of the BRCT domain reduced the heterogeneity of telomere length, 
indicating that the BRCT domain of Rap1 is implicated in telomere length distribution 
[51]. Rap1-deficient mice are viable but display increased recombination due to the role 
of Rap1 in repression of Homology-directed Repair (HDR) [49, 52]. 
TIN2 
TIN2, encoded by TINF2, is a central component of the shelterin complex.  It was 
identified in a two-hybrid screen as a binding partner of TRF1 [53].  It binds TRF2 and 
TPP1 as well as TRF1 and provides a bridge between the double-stranded telomeric 
complex (TRF1 and TRF2/Rap1) and the telomeric complex (POT1 and TPP1) found at 
the G-rich single-stranded overhang (Figure 1.1)[53]. 
TIN2 is a 354-amino acid (40kDa) protein. It binds to the TRFH domain of TRF1 
through its central domain (amino acids 195-284) and to the N-terminus hinge region of 
TRF2 through its amino terminal domain (amino acids 1-195). TIN2 also binds to the C-
terminal TIN2-binding domain of TPP1 through its N-terminal domain. By deleting the N-
terminal domain of TIN2, a recent study revealed that TIN2 is the only link between 
TPP1-POT1 heterodimers and telomeres. If TPP1-POT1 fails to bind to TIN2, the 
connection to the shelterin complex is lost, and the heterodimer can no longer function 
in the end-protection of telomeres [54]. 
TIN2 can bind to TRF1 and TRF2 simultaneously and is important in stabilizing 
both proteins in vivo [40, 55]. Mutational studies reveal that destabilization of either 
TRF1 or TRF2 causes induction of a DNA damage response. Thus, TIN2 contributes to 
the telomere capping function of both TRF1 and TRF2 by stabilizing them or their 
binding at telomeres [41].  
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Loss of TIN2 in mice causes early embryonic lethality, emphasizing the role of 
TIN2 in end-protection [56, 57]. Conditional deletion of Tinf2 in MEFs results in 
decreased localization of all shelterin components to telomeres. In these cells, an ATR-
mediated DNA damage response (mimicking the absence of Pot1a/b) was induced, 
indicating that TIN2 is critical for the protective functions of TPP1-POT1, presumably via 
recruitment of TPP1 (and therefore POT1) to telomeres. There was also a weak ATM-
mediated DNA damage response in these cells, supporting the role of TIN2 in the end-
protection function of TRF2 [57].   
TIN2 was the first shelterin component in which mutations were identified in a 
human disease [58]. Approximately 10% of patients with dyskeratosis congenita (DC) 
have a TINF2 mutation (described in more detail be in section B.5). DC patients with 
TINF2 mutations have extremely short telomeres, indicating a defect in TIN2-dependent 
telomere length control. Although Yang et al. showed that the telomere shortening 
phenotype due to TINF2 mutations is caused by defects related to telomerase 
recruitment in human cells, Frescas and de Lange demonstrated that the effects of the 
mouse counterparts of specific human mutations are telomerase independent [59, 60]. 
Thus, the mechanism by which TINF2-associated DC mutations lead to telomere 
shortening is still unclear. 
POT1 
POT1 is the single stranded telomeric repeat-binding component of shelterin 
(Figure 1.1). It was first cloned based on its homology to the TEBPα (telomere end-
binding protein alpha) subunit of Oxytricha nova [61]. Like TEBPα, the DNA-binding 
domain of POT1 contains two OB (oligosaccharide/oligonucleotide-binding) fold 
domains [62, 63]. Human POT1 has two OB fold domains that recognize the telomeric 
decamer TTAGGGTTAG; the first OB fold binds to the first six nucleotides (TTAGGG) of 
the decamer and the second binds to and protects the four nucleotides (TTAG) at the 3’ 
end of this single stranded DNA sequence [63].  
 The C-terminal domain of POT1, which immediately follows the two N-terminal 
OB domains, binds the central POT1-binding domain of the shelterin component, TPP1.  
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TPP1 is required for recruitment of POT1 to telomeres in vivo [42, 64, 65]. Although 
POT1 itself can bind to DNA in vitro [63, 66], TPP1 increases the affinity of POT1 for 
DNA by ~10 fold [67]. Furthermore, TPP1 binding, but not DNA binding, of POT1 is 
required for POT1 recruitment to telomeres. 
POT1 is known to shield telomeres from DNA damage responses. It represses 
ATR-dependent DNA damage responses and regulates nucleolytic processing of 
telomere ends. POT1 is also involved in two contrasting aspects of the regulation of 
telomere elongation in the presence of telomerase. First, it is proposed that POT1 
functions in a negative feedback mechanism for telomere elongation, whereby it binds 
to the telomeric 3’ overhang and prevents telomeric DNA from being elongated by 
telomerase [68]. Secondly, POT1 together with TPP1 increases the processivity of 
telomerase; thus, it also functions in favor of telomere elongation [69, 70]. 
There are two Pot1 paralogs in mouse; Pot1a and Pot1b. Both are highly 
homologous, having 71-75% amino acid identity to each other and to human POT1. 
They can both bind to DNA, but they have different roles in cells. While Pot1a is known 
to repress the ATR-dependent DNA damage response, Pot1b is responsible for 
regulation of 5’-end resection [71-73]. Pot1a null mice exhibit early embryonic lethality, 
while Pot1b null mice exhibit milder phenotypes such as growth retardation, 
hyperpigmentation, infertility, and intestinal apoptosis [72, 73]. Pot1a/Pot1b double 
knock-out MEFs exhibit growth arrest, endoreduplication, and loss of chromosome end-
protection [64]. Human POT1 is thought to combine the features of Pot1a and Pot1b 
[74]. Interestingly, rescue of Pot1a deficiency in mice with human POT1 also requires 
co-expression of human TPP1. This observation suggests a degree of species 
specificity exists in the interaction between POT1 and TPP1 [65] 
TPP1 
TPP1, encoded by the ACD gene, is the last identified component of shelterin 
(Figure 1.1). It was identified independently, by 3 different groups using mass 
spectrometry analysis of the TRF1-TIN2 complex and two-hybrid screens with TIN2. 
The name was ultimately changed from TINT1, PTOP and PIP1 to TPP1 (resulting from 
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the combination of the first letters of the three former names) [42, 75, 76]. TPP1 is the 
mammalian homolog of the Oxytricha nova chromosome binding protein TEBPβ subunit 
[67].  Human TPP1 is a 544-amino acid (~58 KDa) protein with a debatable N-terminal 
region (1-86 amino acids) (Figure 2.2). The human TPP1 protein is currently thought to 
initiate at Met87, such that the mRNA coding for the preceding 86 residues is now 
believed to be a part of the 5’ UTR of the gene. This is supported by several 
observations. First, amino acids 1-86 lack homology to most mammalian TPP1 
orthologs, including those from mouse, dog, monkey and rat [42]. Second, none of the 
mass spectrometry data that led to discovery of human TPP1 recovered any peptides 
that belonged to the amino acid 1-86 region. Third, the first 86 amino acids are 
dispensable for all known functions of human TPP1 [77].  
In light of the above mis-annotation of the N-terminus of TPP1, the TPP1-OB fold 
domain (87-250 amino acids) is the most N-terminal domain of TPP1 (Figure 2.2). 
Although the crystal structure of the TPP1-OB domain demonstrated that it shares 
typical architecture of the OB-domain containing DNA-binding proteins [69], it does not 
bind DNA directly. The TPP1-OB domain functions in telomerase recruitment to 
telomeres [67, 78, 79]. In addition to its role in telomerase recruitment, the POT1-TPP1 
heterodimer also plays a role as a processivity factor for telomerase by reducing the 
dissociation rate of telomerase from the DNA primer and increasing the translocation 
efficiency (Figure 1.2) [69, 70].  Zaug et al. further demonstrated that species-
specificities exist between mammalian telomerases and their TPP1 (and POT1) 
counterparts [80]. 
Mutagenesis studies revealed a surface of the OB domain of TPP1 including 
seven critical amino acids (E168, E169, E171, R180, L183, L212 and E215), called the 
TEL patch (TPP1 glutamate (E) and leucine (L)-rich patch), that is responsible for the 
interaction between TPP1 and telomerase and recruitment of telomerase to telomeres. 
This domain was also demonstrated to be critical for the processivity of telomerase [81]. 
A subset of these residues was independently identified by two other labs as being 
critical for these aspects of telomerase function [79, 82].  
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The centrally located POT1-binding domain (250-334 amino acids) resides 
immediately C-terminal to the OB-fold domain (Figure 2.2).  As mentioned earlier, TPP1 
binds to the C-terminal TPP1-binding domain of POT1 through this domain and recruits 
it to telomeres [42, 64, 65]. Conditional deletion of TPP1 in MEFs causes release of 
Pot1a and Pot1b from telomeres, resulting in an identical phenotype to conditional 
Pot1a/b double knock out (DKO) cells. These data further highlight the requirement of 
TPP1 for recruitment of POT1 to telomeres [64].  
Based on similarities between the crystal structure of TPP1-OB and Oxytricha 
nova TEBPβ (in the TEBPα/β heterodimer), it was proposed that TPP1 is the missing 
beta-subunit of the TPP1/POT1 complex. As in the case of TEBPα/β, TPP1 is 
responsible for increasing the affinity of POT1 for single-stranded telomeric DNA [64, 
67]. 
The C-terminal terminal domain of TPP1 (425-544 amino acids) is the TIN2-
binding domain (Figure 2.2) [75]. Truncation studies in two-hybrid assays revealed that 
the last 22 residues of TPP1 are critically important for TIN2 binding [83], and the 
presence of TPP1 at telomeres depends on TIN2. As indicated previously, TIN2 
functions as a bridge between double-stranded and single-stranded telomeric regions.  
Although referred to as TPP1 at the protein level, the gene encoding TPP1 is 
named ACD, based on the mouse adrenocortical dysplasia (acd) phenotype, which 
results from a spontaneous autosomal recessive splice site mutation in the Acd gene. 
Homozygous acd mutant mice exhibit pleiotropic phenotypes including defects in the 
adrenal glands, kidneys, and gonads in adult mice as well as caudal regression and 
strain-dependent perinatal lethality [84]. acd mutant embryos  and MEF cells exhibit 
evidence of telomere dysfunction and widespread apoptosis in the caudal portion of the 
embryo [85, 86]. The caudal regression phenotype is thought to be caused by telomere 
dysfunction with subsequent p53-dependent apoptosis during caudal development [86]. 
Due to the splice site defect, the acd allele produces ~2% wild type Acd transcript, thus 
functioning as a hypomorphic allele [85]. MEFs from acd mutant embryos exhibit mild 
telomere deprotection phenotypes, probably due to the small amount of wildtype Tpp1; 
however, knock-down of the remaining Tpp1 in these MEFs results in  phenotypes, 
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similar to Pot1a/b DKO, including strong induction of TIFs, an increased amount of 
single stranded telomeric DNA, and a higher frequency of telomere fusions [65]. These 
data indicate that TPP1 is a unique shelterin component that is not only involved in 
protecting chromosome ends, but is also critical for the extension of these same ends 
by telomerase. 
B. TELOMERASE 
Toward the end of the 20th century, Greider et al. showed a novel activity in 
Tetrahymena cell-free extracts that could add tandem TTAGGG repeats onto telomeric 
primers[87]. It was first proposed that this activity was coming from a telomere terminal 
transferase in eukaryotes. However, in 1989 a novel ribonucleoprotein complex, adding 
de novo telomeric repeats to the end of human telomeres, was identified. This 
ribonucleoprotein complex was named telomerase [88]. In 2009, Elizabeth Blackburn, 
Carol Greider and Jack Szostak were awarded Nobel Prize in Physiology or Medicine 
"for the discovery of how chromosomes are protected by telomeres and the enzyme 
telomerase". In particular, Elizabeth Blackburn and Carol Greider were awarded for the 
discovery of telomerase. 
One problem that emerges due to the linear nature of eukaryotic chromosomes is 
the end-replication problem, because DNA polymerases cannot fully replicate the 
extreme end of chromosomes. DNA polymerases depend on small RNA primers during 
replication. In the growing replication fork, the leading strand is synthesized 
continuously in the 5’ to 3’ direction with one RNA primer starting from origin of 
replication.  However, synthesis of the lagging strand is in the opposite direction with the 
growing replication fork; thus, 5’ to 3’ synthesis must  be completed in fragments, called 
Okazaki fragments, with multiple RNA primers. As one fragment approaches the 5’ end 
of the adjacent fragment, the RNA primer is removed and the two fragments are ligated 
together.  At the very ends of the chromosomes, even if the RNA primer binds to the 
most extreme end of the chromosome, once the RNA primer is removed, it leaves a gap 
at the 5’-end of the lagging strand that cannot be filled by DNA polymerases. Thus, 
chromosomes shorten with each division due to loss of DNA from the 5’ end of the 
lagging strand. In most eukaryotes, the end-replication problem is solved by telomerase, 
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which synthesizes telomeric DNA de novo to compensate the DNA loss from the 5` end 
of the lagging strand during each cell division. Telomerase is a ribonucleoprotein 
composed of a reverse transcriptase protein subunit (TERT) that catalyzes telomere 
repeat addition using templating information provided by its RNA subunit (TERC) [89] 
(Figure 1.2).   
B.1. Telomerase RNA (TERC) 
Telomerase RNA or TERC is one of the major components of the telomerase 
ribonucleoprotein. It is a non-coding RNA containing a region that acts as template for 
the reverse transcriptase subunit, TERT, to synthesize telomeric DNA [90]. The size 
and nucleotide sequence of the RNA component is highly variable in different 
organisms. The length of TERC is ~150 nucleotides in ciliates, ~500 nucleotides in 
vertebrates and ~ 1300 nucleotides in yeast. Although the nucleotide sequence and 
length differs in different organisms, the structure of TERC in different organisms shares 
similar secondary structural features [91]. There are 3 different conserved elements in 
the structure of TERC: the core domain, the trans-activating domain (conserved regions 
4 and 5) and the domains required for stability of TERC in vivo, including the box H/ACA 
domain (conserved regions 6 and 7) (Figure 1.3A). TERC interacts with TERT through 
the core domain and the trans-activating domain independently [92, 93]. 
The core domain contains a template region (conserved region 1), a pseudoknot 
(conserved regions 2 and 3), and a 5’ boundary element for the template (Figure 1.3A). 
The template region contains a primer alignment region that functions in positioning the 
3’ end on the template for telomere synthesis. The telomeric 3’ G-stranded overhang 
acts as a primer, which anneals to the primer alignment region via Watson-Crick base-
pairing. The templating region, which resides immediately upstream or 5’ of the primer 
alignment region, is used to synthesize telomeric DNA at the 3’ end of the annealed 
telomeric primer. It is important to note that the primer alignment region does not 
function as a template for telomeric repeat synthesis; it only positions the primer 
accurately for extension.  Therefore, mutations in the primer alignment region impair 
telomeric repeat synthesis but do not result in non-telomeric mis-incorporations in the 
telomeric primer. The extent of base pairs between the primer and template alters the 
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processivity of telomerase by affecting the translocation efficiency in human and mouse 
telomerase [94].  
The pseudoknot is the most intensely studied element of telomerase RNA. 
Recent studies showing the structural elements of this domain via NMR spectroscopy 
and molecular modeling demonstrated that the folding dynamics of the pseudoknot are 
important for the proper functioning of telomerase [95, 96]. Mutational studies also 
showed that reduction in telomerase activity caused by mutations in the pseudoknot 
domain can be reversed by compensatory mutations that restore the tertiary structure 
[97].  
While the 3’ boundary of the template is defined by its complementary sequence 
to the telomere, the 5’ boundary of the template is defined by a specific RNA element 
located immediately before the template domain. It specifies the site where 
translocation occurs in the process of telomere elongation (Figure 1.2). This element 
shows a high degree of divergence in difference species.  For instance, in human 
TERC, the structure and position of a specific motif, called theP1b helix, are important 
for specifying the 5’ boundary [98], whereas in ciliate TERC, the 5’ boundary element is 
a conserved sequence motif upstream of the template region [99]. 
The trans-activating domain exhibits a high level of homology among different 
organisms. This domain is important in the nucleotide addition processivity of 
telomerase [100]. Entire or partial truncations of this domain cause loss of telomerase 
activity. The effect is due, at least partly, to the role of this domain in interaction with 
TERT [101]. Interruptions in the interaction between TERC and TERT abolish 
telomerase activity [92] . The trans-activating domain of TERC was shown to be 
functional in trans when expressed separately from the core domain of human TERC 
[102]. A stem-loop region, termed P6.1, within the trans-activating domain is essential 
for TERC`s interaction with the telomerase RNA binding domain (TRBD) of TERT. 
Mutational studies revealed that the general structure of this loop is important for 
interaction with TERT. However, there are still specific sequences in the loop structure 
that are important telomerase function [93]. Crosslinking studies mapping the interface 
of interaction between the trans-activating domain of TERC and the TRBD of TERT 
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suggested that the loop is involved in proper folding of TERT by interacting with both the 
TRBD and the C-terminus domain of TERT [103]. The recently reported crystal structure 
of the trans-activating domain of TERC in complex with the TRBD domain of TERT from 
teleost fish Oryzias latipes revealed that both the sequence and the conformation of the 
trans-activating domain are important for this interaction [104]. 
The H/ACA domain is located toward the 3’-teminus of mature TERC in 
conserved region 7(CR7) (Figure 1.3A). It contains a hinge box (H box, consensus 
sequence of ANANNA) and a 5’-ACA-3’ sequence. These two sequence motifs serve as 
binding sites for proteins involved in TERC processing, stability, nuclear localization, 
and telomerase activity [100, 105-107]. Specifically, four proteins, Dyskerin, Nhp2, 
Nop10 and Gar1 bind the H/ACA domain to stabilize TERC in cells [108, 109]. In 
addition to the H/ACA domain, CR7 contains a four-nucleotide motif (5’-UGAG-3’) called 
the Cajal body localization (CAB) box [110]. Cajal bodies are nuclear compartments in 
proliferating/metabolically active cells where snRNPs biogenesis and processing 
occurs. They are implicated in the recruitment of telomerase to telomeres [111]. It is 
known that TERC localizes to Cajal bodies transiently via its CAB box depending of the 
phase of the cell cycle [112]. A WD40 repeat-containing protein WDR79 (TCAB1) 
facilitates localization of telomerase to Cajal bodies, presumably via binding to the CAB 
box of TERC [113, 114]. CR7 also harbors a domain called biogenesis box (BIO box, 5’-
CUGU-3’). As stated in the name, the BIO box functions in the biogenesis and assembly 
of the telomerase RNP [115]. 
Human TERC is synthesized by RNA Pol II and therefore contains a trimethyl 
guanosine cap at its 5’ end. It also contains a guanosine tract that forms a G-
quadruplex, which is proposed to protect it against degradation by nucleases [116].  
This G-quadruplex is opened up by the helicase DHX36/RHAU during the process of 
TERC maturation and telomerase RNP assembly [117]. 
 
B.2. Telomerase Reverse Transcriptase (TERT) 
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TERT is the catalytic component of the telomerase RNP. It was first identified in 
the ciliate Euplotes aediculatus as an RT-like polypeptide shown to have homology with 
the yeast Est2 protein [118, 119]. To date, the only existing crystal structure of a TERT 
protein is from a homolog present in the flour beetle, Tribolium castaneum. The T. 
castaneum TERT (TcTERT) structure displays the three characteristic domains of DNA 
polymerases and reverse transcriptases, namely, the thumb, fingers, and palm domain. 
Indeed, comparison of the crystal structure of TcTERT and HIV RT showed a high level 
of structural similarity. In contrast to TERC, the TERT protein sequence shows a high 
level of conservation among different species. Sequence analysis revealed several 
conserved domains grouped into four structural elements: the N-terminal extension 
domain (containing the telomerase essential N-terminal domain, TEN; and the 
telomerase RNA-binding domain, TRBD), the RT domain (RT), and the C-terminal 
extension (CTE) domain (Figure 1.3B) [120]. It is interesting to note that T. castaneum 
TERT lacks the TEN domain, suggesting that this loss is compensated by the gain of 
additional features in the remaining domains of TERT. 
N-terminal Extension 
The N-terminal extension is the domain containing DNA- and RNA- binding sub-
domains; the telomerase essential N-terminal domain (TEN) and telomerase RNA 
binding domain (TRBD). These two domains are connected via an unstructured linker, 
which confers conformational flexibility to the holoenzyme.  
The TEN domain is the least evolutionarily conserved domain of TERT. It is 
required for telomerase activity in vitro and telomere maintenance in vivo in human, 
yeast and ciliated protozoa [121, 122] . Although it has non-specific RNA binding 
properties, the TEN domain mainly functions in binding single stranded telomeric DNA 
repeats. A region called “dissociates activities of telomerase” (DAT) directs telomerase 
to telomeric substrate in human cells. Mutational studies indicate that the DAT region 
plays a role in affinity of telomerase for its substrate and may serve as an anchor-site 
for telomerase to bind its telomeric substrate. In addition, there are some amino acid 
residues in the TEN domain that are crucial for telomerase activity and telomere 
maintenance, independent of its role in DNA binding. The TEN domain has also been 
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proposed to be involved in the recruitment of telomerase to telomeres [79, 123, 124]. 
Recently, Schmidt et al. identified specific residues in the TEN domain that are 
necessary for recruitment of telomerase to telomeres [125]. 
 The TRBD, the highly conserved domain located between the TEN and RT 
domains, is required for functioning of telomerase both in vivo and in vitro. Through its 
cognate RNA recognition motif, it is responsible for RNA binding that results in the 
formation of the telomerase RNP complex [126, 127]. The TRBD domain interacts with 
the trans-activating domain of TERC, and mutational studies based on the crystal 
structure of the TRBD domain of TERT in complex with the trans-activating domain of 
TERC suggested that trans-activating domain-TRBD recognition is common to most 
eukaryotes [104]. Moreover, a sub-domain, called the T domain, of human TRBD 
contributes to the rate of repeat extension in substrate primer elongation and 
translocation (Figure 1.2). Crosslinking of the trans-activating domain of TERC to the 
TRBD domain of TERT in teleost fish Oryzias latipes revealed that there is a distinct 
binding pocket on TRBD for TERC to bind [103]. 
RT domain 
The catalytic RT domain of TERT is composed of 7 universally conserved 
reverse transcriptase (RT) motifs (Motif 1, 2, A, B’, C, D, E). Motifs 1 and A are 
organized in a putative sub-domain, called “fingers”. This sub-domain is responsible for 
interaction with nucleic acid substrates. Motifs B’ and E are organized in the “palm” 
domain containing the catalytic active site (Figure 1.3B) [120]. There is a triad of 
conserved aspartic acid residues in motifs A and C. As in the case of other 
polymerases, these residues are important for the activity of telomerase by directly 
contributing to nucleotide addition via coordination of two-metal ions [128-130]. The 
palm and fingers sub-domains are connected with a “primer grip” region of Motif E. 
According to molecular models, this loop interacts with the DNA-RNA heteroduplex and 
contributes to single-stranded DNA binding [120, 131, 132].  
The RT domain of TERT can be distinguished from other retroviral or 
retrotransposon reverse transcriptases by a domain called insertion in finger domain 
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(IFD) (Figure 1.3B). Mutational studies reveal that the structural integrity of the IFD is 
important for enzymatic activity through both protein-RNA interaction and RNA-DNA 
interactions. In yeast, a mutation in this domain was shown to abolish multiple repeat 
synthesis by affecting the repositioning of the DNA product relative to the RNA template 
[133].  
Carboxy-Terminal Extension (CTE) 
In addition to the palm and finger domains present in the RT domain of TERT, 
the thumb domain is located within the CTE (Figure 1.3B). Conservation of the motifs in 
this domain is weaker compared to the conservation in the other two domains, 
suggesting the CTE domain may have species-specific functions.  Supporting the 
species specificity, CTE is essential for telomerase activity in humans and in 
Tetrahymena but not in yeast and it is predicted to be absent in C. elegans. 
The C-terminus is composed of a helical bundle that harbors several surface-
exposed loops. These loops are thought to participate in the formation and stability of 
the DNA-RNA heteroduplex in the catalytic site [120, 134]. Mutations in this domain of 
TERT affect enzymatic activity and processivity of human and yeast telomerase. Some 
of these mutations are found to influence the subcellular localization of TERT and 
telomere maintenance in human cells [132, 135-138]. 
Interestingly, addition of epitope tags to the C-terminus of human TERT, as well 
as mutations near the C-terminus, disrupt telomere elongation in vivo, but have no 
effect on in vitro catalytic activity [139]. This indicates that the extreme C-terminus of 
TERT is important for steps of telomere biology other than its catalytic step. 
B.3. Telomerase recruitment to telomeres 
One prerequisite for telomerase functionality is its localization to telomeres. The 
single stranded binding function of telomerase is known to be governed by the POT1-
TPP1 [65].Because POT1 and telomerase bind the same G-rich sequences found at 
chromosome ends, POT1 is thought to be an inhibitor of telomerase. Indeed, the 
addition of POT1 protein decreases telomerase activity in vitro [63]. Interestingly, Wang 
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et al showed that addition of both POT1 and TPP1, but not POT1 or TPP1 alone, 
stimulates telomere processivity by 2-3 fold [69]. This suggests that TPP1 is involved in 
the positive regulation of telomerase. Pull-down experiments showed that TPP1 binds to 
TERT; specifically, the OB fold domain of TPP1 is necessary and sufficient for TPP1-
TERT interaction [67]. It was also demonstrated by Immunofluorescence and 
Fluorescent In Situ Hybridization (IF-FISH) and chromatin immunoprecipitation (ChIP) 
experiments that TPP1 is required for recruitment of telomerase to telomeres, because 
deletion of the OB fold domain of TPP1 disrupts the recruitment of telomerase to 
telomeres [78]. It was also shown that the OB fold domain is sufficient for recruitment of 
telomerase to an artificially constructed non-telomeric locus in the human genome [79]. 
Nandakumar et al. investigated the residues of the OB fold domain that are important 
for interactions with telomerase and via mutagenesis studies, and demonstrated that an 
acidic patch of amino acids on the surface of TPP1, termed the TEL patch, binds to 
telomerase. The TEL patch specifically enables telomerase to be recruited to telomeres 
and to extend telomere ends with high processivity [81]. In addition to data from in vitro 
pull-down and telomerase activity assays showing the importance of the TEL patch for 
telomerase function, it was also shown that the TEL patch mutations decrease the 
extent of telomere elongation by telomerase in cultured human cells [81].  Two 
independent groups have also shown that portions of the TEL patch are required for 
telomerase recruitment and activity [79, 140]. It was suggested that the TEL patch is not 
only important for telomerase recruitment, but also functions as a telomerase activator, 
independent of it role in telomerase recruitment [82]. In addition, by using separation-of-
function mutations, Schmidt et al. recently identified specific residues on the TEN 
domain of telomerase that are necessary for interaction of telomerase with TPP1 and 
for recruitment of telomerase to telomeres [125]. In this study, it was also shown that the 
interaction between the OB-fold of TPP1 and telomerase is a direct interaction by 
rescuing the interaction defect caused by TEN mutations with compensatory mutations 
in the TEL-patch [125]. 
 
B.4. The role of telomerase in stem cells 
20 
 
It is known that in most human somatic cells, except for stem cells and 
lymphocytes, telomerase activity is diminished after birth. Thus, telomeres shorten with 
each cell division, resulting in limited proliferation capacity of most somatic cells. 
Considering the high self-renewal capacity of stem cells, it is not surprising that stem 
cells have at least a low level of telomerase activity.  
Stem cells are pluripotent or multipotent cells. They have self-renewal capability 
and multi-linage differentiation potential [141, 142]. In mammals, there are three general 
types of stem cells: embryonic, germinal, and adult stem cells.  Embryonic stem cells 
(ESCs) reside in the inner cell mass of blastocysts that gives rise to the primary germ 
layers: ectoderm, endoderm and mesoderm. Germinal stem cells (or primordial germ 
cells, PGCs) are the origin of eggs and sperm. Adult stem cells (ASCs) divide and 
differentiate to replenish damaged tissues. For sustained and indefinite proliferation 
potential, all stem cells must maintain their telomere length, which is accomplished by 
expressing telomerase.  
 ESCs are immortal with indefinite proliferation capability in vitro. They have high 
levels of telomerase and long stabilized telomeres. As ESCs differentiate, TERT 
expression is down-regulated, resulting in repressed telomerase activity. Thus, in cells 
differentiated from ESCs, telomeres start to shorten as they proliferate. It has also been 
suggested that telomerase activity confers a stemness factor to ESCs. Inhibition of 
telomerase activity leads to decreased proliferation, and the suppression of TERT 
results in differentiation of ESCs. In contrast, overexpression of TERT in ESCs leads to 
increased cell proliferation and colony-forming ability [143, 144]. It has been shown that 
multiple stemness factors and signaling pathways play roles in maintaining high levels 
of telomerase activity in ESCs. For instance, Kruppel-like factor 4(KLF4), an essential 
component of the pluripotency transcriptional network, is involved in the regulation 
TERT expression in ESCs [145].  
Telomere length is also maintained in the germline. Telomerase activity is 
observed in both immature and mature oocytes in females and in testis in males [146, 
147]. Spermotogonial stem cells were demonstrated to grow in cell culture and 
differentiate into multiple lineages. These observations support the notion that 
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telomerase activity in stem cells can be correlated to self-renewal and multi-lineages 
differentiation capabilities.  Loss of telomerase activity leads to telomere shortening and 
male sterility in successive generations. Although spermatogonial stem cells have 
telomerase activity, spermatozoa lack telomerase activity. When spermatogonia reach 
the growth arrest phase in development, telomerase expression is repressed [148-150].  
ASCs maintain their reservoir of cells by self-renewal and differentiate to more 
specialized tissues to regenerate damaged tissues/organs. These two general 
properties of ASCs are the key to generation of tissues/organs during embryonic 
development and maintenance of tissue/organ homeostasis in adults [141, 142, 151]. In 
aging and degenerative diseases, tissue/organ homeostasis gradually declines, 
eventually resulting in loss of the supply of cells for regeneration upon damage [152]. 
One of factors likely playing a role in this decline is telomere shortening due low level 
telomerase activity observed in ASCs. For instance, in HSCs and also in non-
hematopoietic stem cells, a low level of telomerase activity was detected [153]. Both 
stem cell types still undergo age-dependent telomere shortening in humans, suggesting 
that the level of telomerase activity is not sufficient to maintain telomere length in these 
cells. In particular, there are several lines of evidence confirming the insufficiency of 
telomerase in HSCs. First, HSCs isolated from adult bone marrow exhibit shorter 
telomeres than HSCs from fetal liver and cord blood. Secondly, HSCs from younger 
individuals have longer telomeres than those of older individuals. Third, telomere length 
comparisons between donor and recipient after bone marrow transplantation reveal that 
cells from different lineages undergo telomere loss in response to extensive cell division 
for expansion [154]. In addition to HSCs, stem cell function is known to decline naturally 
with age in various other organs including the forebrain [155-157], skeletal muscle [158, 
159] and skin [160]. Although enhancing telomerase function in aging stem cells has 
been proposed as an avenue to counteract aging, the risk of predisposing toward 
cancer would be expected to outweigh the potential benefits of this approach. 
The critical role of telomerase in stem cells in mice has been demonstrated from 
studies using telomerase knockout/transgenic mice. Deletion of Terc (telomerase RNA 
component) causes reduced tissue renewal efficiency and shorter life span in mice. In 
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addition, male and female infertility, immune-senescence, and reduced regeneration in 
highly proliferative organs including the digestive system, the skin and hematopoietic 
system have been shown in the absence of Terc. It is important to note that because 
mice have very long telomeres; phenotypes associated with telomere shortening can 
only be observed in late generations of telomerase knockout mouse models [161-164]. 
On the other hand, Tert overexpression leads to a decrease in aging-associated 
degenerative and inflammatory processes and an increase in the median survival rate 
of mice [165]. Moreover, Jaskelioff et al. showed that the multi-system degeneration in 
late-generation telomerase-deficient adult mice (with severe telomere dysfunction) can 
be stopped or reversed by reactivation of telomerase without increasing cancer 
incidence [166]. In humans, telomerase deficiency-related diseases including 
dyskeratosis congenita (DC) are relevant to studies of the role of telomerase in stem 
cells. Although these diseases are mostly caused by mutations in a number of different 
genes, the cause of the disease is generally considered to be deficiency of telomerase 
and telomere shortening, leading to reduced function of stem cells. 
In addition to telomere lengthening, recent studies revealed that telomerase or 
TERT functions in multiple different processes that may be important for the function of 
stem cells. Mouse ESCs with TERT overexpression are more resistant to apoptosis and 
oxidative stress in vitro [144]. Moreover, loss of TERT causes mitochondrial defects 
leading to increased levels of reactive oxygen species in mice [167]. Interestingly, TERT 
is also implicated in genome-wide epigenetic regulation of cell differentiation [168]. 
B.5. Telomerase Deficiency and Human Diseases 
The role of telomerase activity in human stem cells has been recently highlighted 
in human diseases caused by mutations in telomerase-associated protein genes, 
including dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis. 
Although the pathophysiology of these diseases is not very clear, telomere attrition due 
to telomerase deficiency, causing dysfunctional stem cells, is thought to underlie the 
disease process. 
Dyskeratosis Congenita (DC) 
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DC is a rare inherited multisystem disorder with an estimated prevalence of 1 in 
1,000,000 (http://ghr.nlm.nih.gov/condition/dyskeratosis-congenita). It was initially 
described by Zinsser in 1906 and recognized as a clinical entity by Engman (1926) and 
Cole (1930). Although it is a rare disease, it is the second-most- common type of 
inherited bone marrow failure syndrome (IBMFS).  Bone marrow failure is found in 
approximately 80 % of DC patients and is known to be the leading cause of death, 
followed by pulmonary disease and cancer.  
DC is a clinically heterogeneous disease. In addition to bone marrow failure, DC 
is often characterized by the triad of nail dystrophy, reticular skin pigmentation of the 
neck/upper chest and oral leukoplakia (Figure 1.4). Although this triad is classical for the 
diagnosis of DC, it may be observed in late stages or it may not be observed at all due 
to variable expressivity and/or incomplete penetrance. Variable expressivity is a genetic 
phenomenon that is used to describe the range of phenotypes for a given genotype. It 
indicates that the phenotype is expressed in varying degrees  in different  individuals. 
Incomplete penetrance is another genetic phenomenon describing incomplete 
genotype-phenotype correlation. In other words, incomplete penetrance indicates that 
each individual with a given genotype may not exhibit the phenotype associated with 
that genotype. 
Patients with DC may also present with several other clinical features including 
pulmonary fibrosis, liver disease, bone abnormalities, dental defects, esophageal 
stricture, immune deficiency, and endocrine, urological or neurological problems. 
Cancer predisposition is another manifestation of DC. Myelodysplatic Syndrome (MDS), 
acute myeloid leukemia (AML), head and neck squamous cell cancer, lymphoma, 
gastrointestinal tract cancer and liver cancer have also been seen in some patients with 
DC. Despite the limitations in sample size and retrospective nature, a study from NCI`s 
DC cohort demonstrated an 11-fold increased risk of cancer in DC patients, and this risk 
is 40% by age of 50 [169]. Since cells from DC patients are characterized by inability to 
maintain their telomeres due telomerase deficiency, it may seem surprising that they 
have increased cancer susceptibility. However, critically shortened telomeres (as in the 
case of DC patients) result in genomic instability leading to telomere fusions, which is 
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implicated in cancer. Moreover, it is noteworthy that DC patients are specifically at the 
risk of developing cancer affecting tissues with high turnover rate [170]. Accumulation of 
mutations due to high turnover rate may also be another underlying mechanism of 
cancer susceptibility in these patients.  
DC is also genetically heterogeneous. It can be inherited in X-linked, autosomal 
dominant (AD), and autosomal recessive (AR) patterns (Table 1.1). In addition, there 
are several de novo germ line mutations that are observed in DC patients such as in 
TERC and TINF2.  
AD-DC exhibits genetic anticipation associated with progressive telomere 
shortening. Genetic anticipation is a phenomenon defined as an increased severity and 
decreased age of disease onset in successive generations. In DC families with TERC 
mutations, genetic anticipation is observed due to progressive telomere shortening as 
described below.  
Currently, the genetic basis is identified in ~70% of DC cases. In these patients, 
DC is caused by germ-line mutations in genes responsible for maintenance of telomere 
length and function. Prior to work reported in this dissertation, nine DC-associated 
genes (DKC1, TERT, TERC, TINF2, TCAB1, NOP10, NHP2, CTC1 and RTEL1) had 
been identified (Table 1.1, Figure 1.5). In Chapter 2, my work demonstrates that ACD is 
a novel DC-associated gene. 
DKC1, NOP10 and NHP2 mutations 
Dyskerin (encoded by DKC1), NOP10 and NHP1 are components of H/ACA 
snoRNP complexes. These complexes are known to be involved in the modification of 
specific uridine residues in newly synthetized ribosomal RNA. H/ACA snoRNPs consist 
of 1 snoRNA and 4 proteins; dyskerin, NOP10, NHP2 and GAR1. While the snoRNA 
guides the complex to the target site of pseudouridylation, dyskerin functions as an 
active pseudouridine synthase enzyme, and NOP10, NHP2 and GAR1 assist in the 
assembly and stability of the complex. 
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In vertebrates, dyskerin, along with NOP10, NHP1 and GAR1, binds to the 
H/ACA box located at the 3’ end of telomerase RNA. This H/ACA complex functions in 
the assembly of telomerase in the nucleus. Knock-down of dyskerin, NOP10 and NHP2 
(but not GAR1) cause a reduction in levels of TERC. Thus, it is not surprising that 
mutations of DKC1, NOP10 and NHP2 have been identified in DC patients.  
DKC1 mutations: 
The most commonly diagnosed form of DC is the X-linked form (Table 1.1). 
Mutations in DKC1 are almost always point mutations causing a single amino acid 
change. However, there are also exceptions, including a 2kb deletion (producing a 
truncated protein), a splice site mutation and a putative promoter mutation. Point 
mutations are usually clustered in 2 regions of the gene: the PUA RNA-binding domain 
and a region near the N terminus. Crystallographic studies have revealed that in the 
archael ortholog of dyskerin, Cbf5, these two regions are in close proximity in the three 
dimensional structure, suggesting that they are involved in the same function [171-173]. 
Thus, it is not surprising that DC mutations in these regions would affect the same 
function of dyskerin. 
Although the underlying mechanism by which dyskerin mutations cause DC is 
not clear, they are known to cause telomere shortening in DC patients. In both humans 
and mice, DC mutations in DKC1 result in low levels of TERC [174-176]. It is proposed 
that low levels of TERC fail to maintain telomere length in stem cells, causing stem cell 
exhaustion in highly renewable tissues, including bone marrow, skin, and fingernails. 
Thus, stem cell exhaustion likely explains the clinical manifestations of DC. 
Interestingly, DNA damage foci formation was observed in mouse cells with pathogenic 
Dkc1 mutations [177]. This suggests that these mutations cause a transient capping 
defect at the telomere, which in turn causes telomere loss.  
As mentioned above, dyskerin is known to be involved in the uridylation of newly 
synthesized rRNA. Although dyskerin mutations do not seem to affect ribosome 
biogenesis in DC patients, they cause defects in ribosome biogenesis and 
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psuedouridylation in mouse cells [174, 176, 178, 179]. Thus, these defects may still be 
playing an undefined role in the DC phenotype in humans. 
Mutations in DKC1 that cause DC have a broad range of severity. In general, affected 
boys develop the characteristic triad of mucocutaneous manifestations in the first 
decade, bone marrow failure in the second decade, and they die from complications of 
bone marrow failure, bleeding and infections in their third decade. There are very 
severe cases in which patients display intrauterine growth retardation, immune 
deficiency and cerebellar aplasia, a syndrome called Hoyeraal Hreiderson Syndrome 
(HH), although there are also less severe cases [180-182].  The variable expressivity of 
a given DKC1 mutation in different individuals suggests the contribution of other genetic 
and/or environmental factors in DC 
NOP10 mutations: 
An autosomal recessive mutation in NOP10 was found in a large 
consanguineous family with 3 affected children. All three children showed the classical 
triad of mucocutaneous features of DC, but only one had bone marrow failure. The 
affected children were homozygous for a R34W mutation and had very short telomeres 
and low levels of TERC. Interestingly, although heterozygous carrier family members 
were asymptomatic, they also had shorter telomeres and lower levels of TERC in 
comparison with healthy controls. However, the effect was not as severe as in the 
affected children [183]. 
NHP2 mutations: 
Two families with autosomal recessive DC and NHP2 mutations have been 
identified. In the first family, the patient was homozygous for a Y139H mutation. The 
patient showed nail dystrophy, thrombocytopenia, growth and mental retardation along 
with other DC manifestations. The second patient was compound heterozygous (V126M 
and X154Arg causing loss of the natural stop codon and extending the protein by 51aa) 
for NHP2 mutations. This patient presented at the age of 12 with classical DC with 
pancytopenia. As expected, short telomeres and low levels of TERC were observed in 
27 
 
these two patients, suggesting that the mechanism of disease mimics that of DC 
patients with DKC1 mutations [184]. 
TERC mutations  
In a large 3-generation family with autosomal dominant DC, a 74-base pair 
deletion at the 3’ end of the gene encoding the RNA component of telomerase, TERC, 
was first identified in 10 members of the family. Their approach was to map the location 
of the gene to chromosome 3q by linkage analysis. Given the role of telomerase 
deficiency previously identified in the X-linked form of DC, TERC was the best 
candidate gene in that region [185]. Since their first description, TERC mutations have 
been found in about 6 % of DC families (Table 1.1). The disease phenotype associated 
with TERC mutations is generally milder than in the X-linked disease [186, 187]. 
However, the severity of the disease increases in successive generations, consistent 
with genetic anticipation due to inheritance of already-shortened telomeres from the 
affected parent [188]. Anticipation is also observed in Terc-null and Tert-null mice. In 
order for Terc-null and Tert-null mice to display abnormalities similar to those found in 
humans, they require breeding for several generations, due to longer telomeres in mice 
[161]. 
Up until now, more than 40 additional TERC mutations, including nucleotide 
substitutions, small/large deletions and insertions have been reported 
(http://telomerase.asu.edu/diseases.html). Although mutations can be found in all 
domains of TERC, most are located in the pseudoknot domain/template domain 
containing sequences required for catalysis, TERT binding, and templating of DNA 
synthesis. Most TERC mutations, including large deletions, cause a reduction of TERC 
levels. The resulting happloinsufficiency is likely a mechanism for pathogenesis of these 
mutations [189]. Haploinsufficiency is also supported by in vitro reconstitution 
experiments, in which expression of mutant TERC in TERC and TERT null cells 
produces only 50% of telomerase activity with respect to that of wild type TERC [190, 
191]. Other TERC mutations mostly results in loss of function through a variety of 
mechanisms, such as reduced TERC stability, reduced association with TERT, 
decreased catalytic activity of telomerase, and changes in the accuracy of telomere 
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repeat addition [189, 192]. Marrone et al. reported two TERC mutations (G178A and 
C180T) that were proposed to be acting on telomerase activity in a dominant negative 
manner [193]. These mutations reside in a region of the pseudoknot that is thought to 
be important for homodimer formation by trans-base pairing [190]. Moreover, patients 
with these two de novo mutations presented with aplastic anemia in first generation 
while published cases with happloinsufficiency require several generations to display 
clinical phenotypes [194]. Surprisingly, these mutations did not show a dominant 
negative effect when they were co-expressed with wild type TERC in telomerase 
negative cells [195]. Thus, TERC happloinsufficency is considered to be the primary 
mechanism of pathogenicity for TERC mutations, similar to the heterozygous TERC 
knockout mouse model [196, 197]. 
TERT mutations 
After the discovery of TERC mutations in DC and aplastic anemia, TERT, as a 
component of telomerase, became a good candidate gene to screen for mutations in 
patients with no DKC1 or TERC mutations. In general, lower penetrance and higher 
level of heterogeneity are seen in disease caused by TERT mutations, compared to 
disease caused by TERC mutations [198]. Several groups found pathogenic TERT 
mutations in patients with aplastic anemia, DC or HH syndrome [199-201].  Since then, 
more than 50 disease–associated mutations have been reported in TERT. These 
mutations have been mapped to different domains of the protein with a slight clustering 
in the reverse transcriptase and the CTE domains 
(http://telomerase.asu.edu/diseases.html). As expected from their localization in TERT, 
most of these mutations affect the catalytic activity or repeat processivity of telomerase 
[186, 192, 193, 199, 202, 203]. TERT mutation thus far has been reported to have 
dominant negative effects; thus the mechanism of pathogenesis in TERT-associated 
diseases is generally accepted to be due to haploinsufficiency [199]. 
Disease caused by TERT mutations differs from TERC-associated diseases in 
terms of penetrance and heterogeneity. Although individuals who are homozygous or 
compound heterozygous for TERT mutations present with severe manifestations of 
disease, heterozygous TERT mutations generally have lower penetrance with 
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asymptomatic or mildly affected carriers. The heterogeneity of TERT-associated 
diseases is also higher than in TERC-associated diseases. It has been suggested that 
there are fewer TERT null mutations identified in patients, thereby, most patients with 
TERT mutations still have residual telomerase activity, contributing to the low 
penetrance and variable expressivity. Genetic anticipation and other genetic/ 
environmental factors likely also play role in the reduced penetrance and the highly 
heterogeneous phenotype[198]. 
TINF2 mutations 
Germline mutations in TINF2, encoding the shelterin protein TIN2, are known to 
cause autosomal dominant DC. For the first time, Savage et al. identified a mutation in 
the TINF2 gene, causing DC in a large family (with no mutations in TERT, TERC or 
DKC1) via genetic linkage analysis [58]. Affected members of the family had a 
heterozygous K280E mutation and very short telomeres. Subsequently, the same group 
found mutations in four of eight additional patients with genetically unidentifiable DC; 
three with R282H and one with R282S. All of the probands presented with severe DC-
like features earlier than four years of age and had very short telomeres. One patient 
with R282H had Revesz Syndrome [204], characterized by bilateral retinopathy, 
developmental delay, the DC triad, and cerebellar hypoplasia. In order to further 
establish the role of TINF2 mutations in DC, Walne et al. sequenced a large cohort of 
patients with genetically uncharacterized DC [205]. They identified TINF2 mutations, 
mostly de novo, in 33 out of 175 DC patients. Strikingly, 21 of the mutations were 
identified in amino acid R282, changing it either to H (14) or to C(7).  Interestingly, 32 of 
the 33 patients had severe forms of DC with very short telomeres compared to other DC 
subtypes. Most of them had developed aplastic anemia by the age of 10.  In addition to 
missense mutations, there are also patients with severe DC, including Revesz 
syndrome, who have nonsense and frameshift mutations [206]. Although the general 
trend of increased severity in DC patients with TINF2 mutations was confirmed by other 
studies [206, 207], rare  individuals with TINF2 mutations were found to be silent 
carriers or to present with less severe forms of DC [58, 205]. 
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As mentioned above, the mechanism of action of pathogenic TINF2 mutations 
has yet to be elucidated. Although very short telomeres in patients with TINF2 mutations 
is a clue that the effect is on telomere length maintenance, there are contradicting data 
on the subject in human and mouse cells. While overexpression of pathogenic TINF2 
mutations in human cells was found to mimic the telomere shortening phenotype of DC 
through deficiency in TERC association, no decrease in telomere length was observed 
in human cells with these mutations in an independent study [59]. The latter study also 
revealed that the effect of TINF2 mutations is independent of telomerase in mouse cells 
[60].In a separate study, TIN2 was shown to bind a protein called HP1γ. HP1γ binds to 
telomeres in S phase, where it functions to maintain cohesion of sister chromatids by 
interacting with cohesin protein complexes. Thus, it prevents sister telomere loss. The 
HP1γ binding site on TIN2 was shown to be required for sister telomere cohesion, and 
pathogenic mutations in this region of TIN2 cause failure in telomere length 
maintenance. Interestingly, TINF2 mutations in DC cluster at the consensus binding site 
for HP1γ, and these mutations have been shown to block HP1γ binding. Furthermore, 
DC patient cells were found to be defective in sister telomere cohesion. These 
observations suggest that defects in HP1γ binding, and hence defective sister telomere 
cohesion, likely play a significant role in the pathogenesis of the disease [208, 209]. 
When pathogenic TINF2 mutations were overexpressed in human cells, the resulting 
telomere shortening was less drastic compared to the very short telomere lengths 
observed in patient cells [208]. In order to explain this discrepancy, the authors 
speculated that the effect of TINF2 mutations could be on embryonic telomere 
maintenance, in which sister telomere cohesion is involved in a recombination like 
mechanism [210, 211]. 
TCAB1 mutations  
TCAB1, also known as WDR79 or WDR53, is a WD40 repeat-containing protein 
that binds to the CAB box within the H/ACA domain of TERC [114, 212]. As mentioned, 
the CAB motif is required for trafficking of telomerase to Cajal bodies. The accumulation 
of telomerase in Cajal bodies is crucial for translocation of telomerase to telomeres 
[213]. Depletion of TCAB1 by RNA interference causes disruption of the association of 
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TERC with both Cajal bodies and telomeres. Thus, TCAB1 plays a key role in the 
trafficking and translocation of telomerase.  TCAB1 depletion also leads to telomere 
shortening in cancer cells, suggesting its involvement in the control of telomere 
synthesis [113]. 
Zhong et al. sequenced the TCAB1 gene in a cohort of DC patients with no 
known DC-associated mutations [214]. Two patients with telomere lengths below the 
first percentile were found to be compound heterozygous for TCAB1 mutations. Both of 
the patients presented with classic DC, including the triad of mucocutaneous features 
and bone marrow failure. TCAB1-associated DC was inherited in an autosomal 
recessive manner in these two families. The mother and father of each proband carried 
one of the TCAB1 mutations, although they had no clinical manifestations and normal 
telomere lengths.  The mutations (F164L and R398W; H376Y and G435R) are in 
conserved residues of TCAB1. Epitope-tagged proteins with the pathogenic mutations 
were found to exhibit reduced expression in HeLa cells compared to the wild type 
protein, and the localization of mutant proteins to Cajal bodies was impaired. Similar 
mislocalization defects were observed in patient-derived cells. In addition to TCAB1 
mislocalization, dyskerin failed to localize in Cajal bodies, and TERC mislocalized to 
nucleoli instead of Cajal bodies in patient-derived cells [214]. Thus, pathogenic TCAB1 
mutations impair the trafficking of telomerase, causing the failure of telomerase to be 
localized in Cajal bodies for its subsequent translocation to telomeres. 
CTC1 mutations 
Conserved telomere maintenance component 1 (CST telomere maintenance 
component 1 or CTC1) is a component of a trimeric complex, called CST 
(CTC1/STN1/TEN1). The CST complex localizes to telomeres and functions in telomere 
maintenance through telomere replication [215, 216] but the exact mechanism by which 
it functions has not yet been elucidated.  Although  it is involved in the inhibition of 
telomerase function both in vivo and in vitro [217], the CST complex was proposed to 
function mainly in priming the filling of the C-strand gap by recruiting pol α primase, 
subsequent to extension of the 3’overhang by telomerase [218, 219]. In particular, 
CTC1 is known to bind single stranded DNA and stimulate pol α primase activity [215, 
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216, 220]. In addition, Gu et al. suggested that CTC1 contributes to efficient telomere 
replication at telomeres by promoting the restart of lagging strand telomere synthesis at 
stalled replication forks [221].   
Two independent studies revealed that compound heterozygous mutations in 
CTC1 cause Coats plus syndrome, which is characterized by short telomeres and other 
phenotypes overlapping with DC [222-224]. Subsequently, Keller et al. identified 
compound heterozygous mutations in CTC1, in a patient with DC [225]. Interestingly, 
the mutations found in the DC patient are identical to the mutations found in patients 
with Coat plus syndrome [222, 223], thus strengthening the role of CTC1 mutations in 
the pathogenesis of both diseases. The differences in the phenotypic presentations of 
these patients are likely due to genetic and/or environmental modifying factors [225, 
226] also identified biallelic CTC1 mutations in 6 patients with DC and related bone 
marrow failure syndromes. Interestingly, the spectrum of phenotypical features in these 
patients with CTC1 mutations was highly variable, even with regard to telomere length.  
Phenotypes observed in Ctc1 knockout mice are similar to the clinical 
manifestations of some patients with CTC1 mutations, including bone marrow failure. 
Moreover, defective telomere replication and massive telomeric loss observed in cells 
from Ctc1 knockout mice may also account for the effect of CTC1 mutations in patients 
with short telomeres [221, 226]. Chen et al. functionally characterized disease-causing 
CTC1 mutations, including point mutations and small deletions, and showed that they 
are generally defective in the telomere replication function of the CST complex, leading 
to accumulation of single-stranded gaps at telomeres [227]. All patients described to 
date have missense mutations; none of them carry two loss of function mutations, 
suggesting that complete loss of CTC1 function might be lethal.  When mutant proteins 
with missense mutations were co-expressed with wild type CTC1, they showed a 
dominant–negative effect on the telomere replication function of CST.  In conclusion, all 
CTC1 mutations result in the accumulation of single-stranded gaps at telomeres, 
indicating that the replication defect is the most common mechanism of pathogenesis.  
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RTEL1 mutations 
Regulator of telomere elongation helicase 1 (RTEL1) is an evolutionarily 
conserved DNA helicase, playing at least 2 critical roles in telomeric integrity [228]. 
First, it prevents replication fork stalling during telomeric DNA replication by removing 
the telomeric G-quadruplex, thereby suppressing telomeric fragility. Second, it is 
thought to be involved in the disassembly of t-loop structures at certain stages of the 
cell cycle to prevent catastrophic telomere loss [34, 229]. 
RTEL1 mutations were recently identified in a small cohort of DC patients by 
whole-exome sequencing [230]. Probands from two families had Hoyeraal Hreidarsson 
(HH) syndrome and a proband from a third family had a DC-like syndrome. Siblings with 
HH in the first family showed autosomal dominant inheritance of a R1010X mutation. 
Their mother, who has short telomeres, also carries the mutation.  The proband in the 
second family had compound heterozygous mutations in RTEL1 (E615D and R998X) 
with autosomal recessive inheritance. Genetic anticipation was observed in both 
families associated with telomere shortening. The proband from the third family had an 
A645T mutation associated with short telomeres. Both R1010X and R998X are 
predicted to result in loss of PIP (PCNA-interacting peptide) motifs in RTEL1. The 
phenotypes produced by these mutations are predicted to be similar to RTEL1-PIP box 
mutant mouse-like phenotypes, including replication fork instability [231]. E615 and 
A645 are highly conserved residues in the C-terminal helicase domain, which plays a 
key role in the helicase activity of RTEL1 and may explain the telomere shortening 
phenotypes [230]. 
In an independent study of 7 families, 11 biallelic RTEL1 mutations with 
autosomal recessive inheritance were identified in 10 individuals with HH syndrome. 
Cells harboring these mutations showed defects in resolution of t-loops, which may be a 
mechanism for telomere shortening in these patients [232]. In a third study of two 
families, using an approach combining whole-genome linkage analysis and exome 
sequencing, compound heterozygous RTEL1 mutations were identified in three patients 
with HH syndrome. The mutations reside either at the catalytic core of RTEL1 or in the 
cysteine rich consensus sequence, C4C4-type RING-finger motif [233]. Although the 
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role of the C4C4-type RING-finger motif is not fully known, it is involved in protein-
protein interactions and is predicted to be important for the metal ion binding function of 
RTEL1 [234]. 
In conclusion, there are a number of DC mutations identified throughout the 
RTEL1 gene. The underlying pathogenic mechanism of each mutation remains to be 
determined but is likely associated with either increased telomeric fragility or increased 
t-loop excision. 
Aplastic Anemia (AA) 
AA is characterized by peripheral blood pancytopenia due to inefficient 
hematopoiesis and hypocellular bone marrow. Mutations in telomerase components 
(TERT: [201]; TERC: [235]) are common in AA patients and accordingly, reduced 
telomerase activity and telomere loss are characteristic of AA. Indeed, AA is a common 
manifestation in DC patients. In addition to exhibiting significantly short telomeres, AA 
patient cells display an increased frequency of chromosomal breaks and aberrations, 
including monosomy 7 in some cases [236]. As with DC, clinical features of AA can be 
explained by a reduction in stem cell reserves, caused by the failure of self-renewal 
capacity of stem cells due to telomerase deficiency. Given the primary clinical 
manifestations in blood cells and bone marrow, hematopoietic stem cells are the most 
significantly affected stem cell population in AA patients. 
Idiopathic Pulmonary Fibrosis (IPF) 
IPF is a chronic, progressive, fatal lung disease characterized by dyspnea, lung 
scarring and abnormal gas exchange. It is also a common manifestation of other 
telomerase-related diseases, specifically, the autosomal dominant form of DC. 
Mutations in TERT and TERC are currently the most identifiable genetic cause of IPF, 
with germline mutations in TERT and TERC observed in up to one-sixth of patients with 
IPF [237]. However, one study suggested that the prevalence of sporadic mutations in 
TERC and TERT in IPF patients is considerably lower [238]. Two independent studies 
using different approaches have demonstrated that patients with heterozygous TERT 
and TERC mutations have shorter telomere lengths in their white blood cells compared 
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to age-matched controls. Continuous shortening of telomeres leads to premature 
senescence in alveolar epithelial cells, which explains the underlying basis of the 
disease. Due to the time that is needed for telomeres to reach critical shortening, 
differences in mean telomere lengths between carriers and age- matched controls are 
higher in older mutation carriers of a given family. This also explains the age-dependent 
nature of IPF. In addition, it was proposed that IPF and bone marrow failure form a 
syndrome complex [239]. Parry et al. showed that in 10 patients from 10 families, co-
occurrence of IPF and bone marrow failure were predictive of germline mutations of 
TERT or TERC with 100% accuracy [240]. In these families, it was proposed that the 
pattern of disease switches from being lung-predominant to being bone marrow-
predominant in successive generations [240]. 
B.6. The role of telomerase in cancer 
The earliest connection between telomeres and cancer was from studies in 
primary human fibroblast cells. Hayflick showed that fibroblasts have limited replicative 
potential such that they undergo ~60-80 population doublings before they enter a non-
replicative senescent state [241]. On the other hand, cancer cells keep dividing 
indefinitely in cell culture. Moreover, progressive telomere shortening was observed in 
normal fibroblast cells but not in cancer cells. The connection between these two 
observations provided the first clue for the association between telomere length 
maintenance and cancer. Since the first observation of telomerase expression in 
association with cancer in 1994, the number of studies on this subject has increased 
exponentially [242]. 
The canonical role of telomerase in cancer is to maintain telomere length. Normal 
somatic cells, as mentioned above, have limited replicative potential. Due to the lack of 
telomerase expression, they undergo telomere shortening with each division and enter 
replicative senescence. Cells with defective cell cycle check points such as inactivated 
p53, Rb, or p16, bypass this senescence state and continue to divide. As they divide, 
telomere erosion persists until the cells reach a crisis state, in which chromosome ends 
become uncapped and shortened ends fuse together. This sequence of events results 
in chromosomal instability and eventually apoptosis. Replicative senescence and crisis 
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are mechanisms used by the cell to protect against cancer. However, in some cases 
cells can acquire a mechanism to maintain the length of their telomeres before crisis. 
The most common way of maintaining telomeres is to activate telomerase expression, 
which is believed to be an important step in the progression towards carcinogenesis.  
In addition to its role in telomere length maintenance, telomerase has been 
suggested to have other roles in carcinogenesis.  It is known that telomerase-negative 
tumor-derived cells maintain their telomere length by a mechanism called Alternative 
Lengthening of Telomeres (ALT). Stewart et al. used a cell line that maintains telomere 
length by ALT to demonstrate that the role of telomerase activity in carcinogenesis 
cannot be substituted by the ALT mechanism [243]. Thus, telomerase is thought to have 
additional, probably extra-telomeric roles in tumorigenesis. It was demonstrated that 
telomerase can also affect proliferation of epithelial cells by modulating the expression 
of growth-promoting genes. Ectopic expression of telomerase in human mammary 
epithelial cells leads to a decrease in the requirement of mitogens to promote cell 
growth. This effect was shown to be mediated through the inhibition of expression of 
growth-promoting genes such as EGFR [244]. Moreover, telomerase functions as a 
transcriptional modulator of Wnt/β catenin signaling, which is implicated in several 
different cancer types. In addition to its putative role in cell proliferation, TERT is also 
involved in the suppression of apoptosis. Taken together, these observations support 
the hypothesis that telomerase has telomere-independent roles in tumorigenesis [49]. 
Deregulation of telomerase is a common feature of cancer cells. In approximately 
90% of cancers, telomerase expression is upregulated. Although the exact mechanism 
is not clear in all cases, it is thought to occur through several different mechanisms 
including epigenetic deregulation and amplification of the TERT gene locus [245]. 
Another interesting hypothesis is that normal stem cells, which naturally exhibit 
telomerase activity, are progenitors in tumors [246]. Recently, two independent groups 
discovered causal promoter mutations in the TERT gene creating de novo Ets/TCF 
transcription factor binding motifs. Horn et al. identified a TERT promoter mutation in a 
large family with melanoma. In reporter gene assay studies, this mutation was shown to 
result in a two fold induction in transcription of TERT  [247]. When they screened tumors 
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from unrelated families with melanoma, they identified recurrent mutations in the TERT 
promoter, resulting in the creation of Ets/TCF transcription factor binding motifs. Huang 
et al also identified two independent highly recurrent mutations in promoter region of the 
TERT gene, which generate de novo Ets/TCF transcription factor binding motifs and 
induce a two-to four fold induction in transcription of TERT in reporter gene assay 
studies [248]. Moreover, they found these mutations in cell lines from different types of 
tumors, including bladder and hepatocellular cancer cells. These two studies 
demonstrated that promoter mutations in the TERT gene leading to telomerase 
activation are an important tumorigenic mechanism [247, 248]. In addition, the role of 
telomerase reactivation in the rapid progression of prostate cancer was demonstrated in 
a mouse model with short dysfunctional telomeres [249]. The same group also showed 
that in identical telomere dysfunction settings, when reactivation of telomerase is 
inhibited, cancer cells reprogram their transcription of mitochondrial genes to adapt to 
the loss of telomerase activity and acquire the ALT mechanism to maintain telomere 
length [250]. 
Considering the role of telomerase in tumorigenesis, there has been a lot of effort 
to devise telomerase-based therapies against cancer. One strategy is vaccination 
against tumor associated antigens, although the results of clinical trials have not yet 
been very successful.  For instance, vaccination with GV1001, a 16-mer TERT peptide, 
seemed to generate a specific immune response in non-small cell lung cancer [251], 
whereas no immune or tumor response was seen in patients with hepatocellular 
carcinoma and cutaneous T cell lymphoma [252, 253]. Another popular approach is 
gene therapy involving targeting either the RNA of TERC or TERT expression by 
antisense oligonucleotides (ASOs). The most well-studied ASO is imetelstat 
(GRN163L), a lipid-modified 13-mer oligonucleotide complementary to TERC [254]. 
Studies in preclinical models showed therapeutic potential of imetelstat; thus, it is 
currently being tested in clinical trials [255, 256]. 
Future studies in the field of telomeres and telomerase will provide new insights 
into the regulation and maintenance of stem cells as well as the complex relationship 
between telomeres and cancer development.  
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C. INTRODUCTION TO DISSERTATION 
As discussed in previous sections, DC is an inherited bone marrow failure 
disorder, characterized by short telomeres. Although the genetic cause of DC is not 
always identified; in 70% of cases, DC is the result of germline mutations in nine 
telomere biology genes including TERC, TERT, DKC1, NHP2, NOP10, 
TCAB1(WRAP53), RTEL1, TINF2 and CTC1 (Figure 1.5).  
In Chapter 2, I report for the first time that mutations in ACD/TPP1 can cause of 
DC. We identified a single-amino-acid deletion in the TEL patch and a missense 
mutation in the TIN2-binding domain of TPP1 in a patient with a severe variant of DC, 
Hoyeraal-Hreidarsson (HH) syndrome. Functional characterization of these mutations 
revealed that the deletion in the TEL patch abrogates telomerase recruitment and also 
impairs the enzymatic processivity of telomerase, whereas the missense mutation has 
milder effects characterized by reduced binding to TIN2. 
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Figure 1.1: Schematic diagram of shelterin complex.  There are six known 
subunits of shelterin. TRF1 and TRF2 bind to double-stranded telomeric DNA. 
TIN2 can bridge TRF1 and TRF2. POT1 binds to single-stranded telomeric DNA. 
POT1 is recruited to telomeres by TPP1. TPP1 is recruited to telomeres by TIN2. 
Rap1 is a binding partner of TRF2. 
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Figure 1.2: Telomeric repeat synthesis by telomerase.  RNA component of 
telomerase (TERC, shown in orange) functions as template for the synthesis of 3’ 
end.  Reverse transcriptase component of telomerase (TERT, shown in green) 
synthesizes the complementary strand until 5’ end of template is reached (1). Then, 
telomerase translocates to newly synthesized 3’ end (2).  After the translocation of 
telomerase, second round of synthesis is performed by TERT (3). Primase and DNA 
polymerase synthesize the complementary strand of 3’ overhang. 
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Figure 1.3:  Domain structure of human TERC and TERT.  (A) Schematic 
representations of the secondary structures of TERC. CR4/CR5, CR7, BIO box, 
CAB box, H/ACA domains, template boundary element (TBE), and 5’ 
trimethylguanosine (TMG) cap are indicated. Pseudoknot is indicated with blue 
box. TMG (B) Domain structure of human TERT. The N-terminal extension, 
telomerase RNA-binding domain (RBD), fingers, palm, thumb, and IFD are 
shown. Adopted from Hukezalie and Wong (2013)[3]. 
TERC 
TERT 
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Figure 1.4: DC diagnostic triad. A. Dystrophic fingernails. B. Lacey, reticular 
pigmentation of the neck and upper chest. C. Oral leukoplakia. Adopted from Savage 
and Alter (2009) [2] 
 
Figure 1.5: DC genetics. Germline mutations in telomerase subunit genes (TERC 
and TERT) or genes involved in telomerase biogenesis (DKC1, NOP10, NHP2, and 
WRAP53) are commonly associated with DC. Additionally, mutations in telomere 
biology genes (TINF2, CTC1, and RTEL1) are also observed in certain cases of DC. 
XLR: X-linked recessive, AD: Autosomal dominant, AR: Autosomal recessive. 
Adopted from Savage (2014) [1] 
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Table 1.1: Known genetic causes of DC 
Gene, gene product name(s) Inheritance %DC 
DKC1,  Dyskerin X-linked recessive 22 
NOP10,  NOP10, NOLA3,  Nuclear 
protein family A, member 3 
Autosomal recessive <1 
NHP2,  NHP2, NOLA2, Nuclear 
protein family A, member 2 
Autosomal recessive <1 
TERC, TERC, Telomerase RNA  Autosomal dominant 6 
TERT,  TERT, Telomerase Reverse 
Transcriptase 
Autosomal dominant 
Autosomal recessive 
11 
TINF2, TIN2, TERF1 (TRF1)-
Interacting Nuclear Factor 2 
Autosomal dominant 20 
TCAB1, TCAB1, Telomerase Cajal 
Body Protein 1 
Autosomal recessive 3 
CTC1, CTC1, Conserved Telomere 
Maintenance Component 1 
Autosomal recessive 1-5 
RTEL1,  RTEL1, Regulator of 
Telomere Elongation Helicase 1 
Autosomal dominant 
Autosomal recessive 
8 
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CHAPTER 2: HOYERAAL-HREIDARSSON SYNDROME CAUSED BY A GERMLINE 
MUTATION IN THE TEL PATCH OF THE TELOMERE PROTEIN TPP1 
ABSTRACT* 
Germline mutations in telomere biology genes cause dyskeratosis congenita 
(DC), an inherited bone marrow failure and cancer predisposition syndrome. DC is a 
clinically heterogeneous disorder diagnosed by the triad of dysplastic nails, abnormal 
skin pigmentation, and oral leukoplakia. Hoyeraal-Hreidarsson syndrome (HH), a 
clinically severe variant of DC, also includes cerebellar hypoplasia, immunodeficiency, 
and intrauterine growth retardation. Approximately 70% of DC cases are associated 
with a germline mutation in one of nine genes, the products of which are all involved in 
telomere biology. Using exome sequencing, we identified mutations in Adrenocortical 
Dysplasia Homolog (ACD) (encoding TPP1), a component of the telomeric shelterin 
complex, in one family affected by HH. The proband inherited a deletion from his father 
and a missense mutation from his mother, resulting in extremely short telomeres and a 
severe clinical phenotype. Characterization of the mutations revealed that the single-
amino-acid deletion affecting the TEL patch surface of the TPP1 protein significantly 
compromises both telomerase recruitment and processivity, while the missense 
* Material in this chapter is modified from: 
Kocak H,  Ballew BJ, Bisht K, , Boland JF,  Eggebeen R, Hicks BD, Suman S, O’Neil A, Giri 
N, NCI DCEG Cancer Genomic Research Laboratory; NCI DCEG Cancer Sequencing Working 
Group, ; Maillard I,  Alter BP, Keegan C , Nandakumar J, Savage SA (2014)  “Hoyeraal-Hreidarsson 
syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1”. Genes 
Dev. 28(19):2090-102. 
The experiments shown in figures 2.4B, 2.5, 2.6, 2.7, 2.8 were performed by me. The 
experiments shown in figures 2.9A, D, 2.10 and figure 2.11A, B were performed by me in 
collobaration with Kamlesh Bisht. I contributed to the experiments in figures 2.11C, D by doing 
transient transfections for the ChIP assay. 
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mutation in the TIN2-binding region of TPP1 is not as clearly deleterious to TPP1 
function. Our results emphasize the critical roles of the TEL patch in proper stem cell 
function and demonstrate that TPP1 is the second shelterin component (in addition to 
TIN2) to be implicated in DC. 
 
INTRODUCTION 
Dyskeratosis congenita (DC) is a rare cancer-prone inherited bone marrow 
failure syndrome caused by dysfunctional telomere maintenance [170, 257]. It is 
diagnosed clinically by the presence of the classic triad of nail dysplasia, lacy skin 
pigmentation, and oral leukoplakia. Substantial clinical heterogeneity exists among DC 
patients, even within affected families: Patients may also have pulmonary fibrosis; liver 
disease, esophageal, urethral, or lacrimal duct stenosis; developmental delay; dental 
and ophthalmologic abnormalities; and/or other complications [170]. Patients with DC 
are at a very high risk of bone marrow failure and cancer, particularly myelodysplastic 
syndrome, acute myelogenous leukemia, and solid tumors (usually squamous cell 
carcinoma of the head/neck, skin, or anogenital region) [258]. DC is characterized on a 
molecular level by blood leukocyte telomere lengths less than the first percentile for 
age, the result of germline mutations in telomere biology genes [259].  
Multiple modes of inheritance are associated with DC [183, 184, 225, 226, 232, 
233, 260, 261].  X-linked recessive (XLR) DC is caused by DKC1 (MIM 300126) 
mutations. Autosomal dominant (AD) DC can be caused by mutations in TERC (MIM 
602322; encodes the telomerase RNA template TR), TERT (MIM 187270; encodes the 
telomerase reverse transcriptase), RTEL1 (MIM 608833), or TINF2 (MIM 604319). 
Autosomal recessive (AR) inheritance of mutations in TERT, RTEL1, CTC1 (MIM 
613129), NOP10 (MIM 606471), NHP2 (MIM 606470), or WRAP53 (MIM 612661) also 
cause DC. Germline mutations in these genes account for ∼70% of DC cases.  
Hoyeraal-Hreidarsson (HH) syndrome is a clinically severe variant of DC marked 
by immunodeficiency [262], intrauterine growth retardation (IUGR), developmental 
delay, and cerebellar hypoplasia; the latter is characteristic of HH [263]. HH patients 
have extremely short telomeres, even in comparison with other DC patients [259]. 
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Mutations in a subset of DC-associated genes (DKC1 [XLR], TINF2 [AD], TERT [AR], 
and RTEL1 [AD and AR]) have been shown to cause HH.  
TPP1, a protein encoded by the Adrenocortical Dysplasia Homolog (ACD) gene 
(MIM 609377), is one of the core components of the telomeric shelterin complex (Figure 
2.1). TPP1 performs multiple functions at the telomere, mediated by distinct protein 
domains (Figure 2.2A). The central domain of TPP1 facilitates formation of a 
heterodimer with POT1 (MIM 606478); this complex binds and protects the single-
stranded tail found at all chromosome ends [63, 75, 76]. Via the C-terminal domain, 
TPP1 binds TIN2, forming a bridge between POT1 and the dsDNA-binding TRF1/TRF2 
(MIM 600951/602027) components of shelterin [57]. By physically linking two critical 
shelterin components, TPP1 plays a central role in protecting chromosome ends [264].  
In addition to its critical role in end protection, TPP1 is also responsible for 
recruiting telomerase to chromosome ends, thereby facilitating telomere extension 
(Figure 2.1). A group of surface-exposed amino acids in the N-terminal OB domain of 
TPP1 (TPP1-OB), collectively termed the TEL patch, mediates the interaction of TPP1 
with telomerase, facilitates telomerase recruitment to telomeres, and stimulates 
telomerase enzymatic processivity (Figure 2.2A; [67, 69, 70, 78, 79, 81, 140]. An intact 
TEL patch is required for both telomere lengthening and HeLa cell proliferation [81, 
265]. Because TPP1 depends on binding to TIN2 for its own recruitment to telomeres, 
the TPP1–TIN2 interaction described above is also important for telomerase recruitment 
[67, 78, 79]. 
Here, we report the identification of a single-amino-acid deletion in the TEL patch 
of TPP1 and a missense mutation in the TIN2-binding domain of TPP1 in an HH 
proband who is negative for mutations in other DC-associated genes. Characterization 
of these mutants revealed that the deletion in the TEL patch severely compromises both 
telomerase recruitment and processivity, whereas the missense mutation has less 
severe effects.  
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MATERIALS AND METHODS 
Patients 
Patient NCI-275-1 and his family were participants in an institutional review board 
(IRB)-approved longitudinal cohort study at the National Cancer Institute (NCI) entitled 
“Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure 
Syndromes” (NCI 02-C-0052, ClinicalTrials.gov Identifier: NCT00027274).  This study 
includes comprehensive family history and individual history questionnaires, detailed 
medical record review, and biospecimen collection [258].  The proband, his older sister, 
younger twin sisters, mother, and father were evaluated at the National Institutes of 
Health (NIH) Clinical Center by the Inherited Bone Marrow Failure Syndromes (IBMFS) 
study team. Telomere length was evaluated by flow cytometry with fluorescent in situ 
hybridization (flow FISH) in leukocytes [266].   
Exome Sequencing and Analysis 
Whole exome sequencing for family NCI-275 was performed at the NCI’s Cancer 
Genomics Research Laboratory as previously described [261], with the following 
modifications.  Genomic DNA libraries were prepared and amplified with the Bioo 
Scientific NEXTflexTM Pre-Capture Combo Kit (Bioo Scientific, Austin, TX, USA) 
according to the manufacturer’s protocol, then cleaned with Agencourt AMPure XP 
Reagent (Beckman Coulter Inc, Brea, CA, USA) according to the Bioo-provided 
protocol.  Amplified sample libraries were quantified using Quant-iT™ PicoGreen 
dsDNA Reagent (Life Technologies, Carlsbad, CA, USA).  Prior to hybridization, four 
amplified sample libraries with unique index adapters were combined in equal amounts 
(275 ng) into 1.1 μg pools for multiplex sequence capture.  Exome sequence capture 
was performed with NimbleGen’s SeqCap EZ Human Exome Library v3.0, targeting 64 
Mb of exonic sequence (Roche NimbleGen, Inc., Madison, WI, USA).  Exome-enriched 
libraries were amplified and purified as above.  The resulting post-capture enriched 
multiplexed sequencing libraries were sequenced as described [261]. Approximately 
90% of all targeted bases were covered at a depth of 15X or greater (Table 2.3).  
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Sequence reads were trimmed using the Trimmomatic program [267], then 
aligned to the hg19 reference genome using Novoalign software version 2.07.14 
(http://www.novocraft.com), Picard software version 1.67 (http://picard.sourceforge.net/) 
and the Genome Analysis Toolkit (GATK, http://www.broadinstitute.org/gatk/) [268] as 
described previously [261].  Variant discovery, genotype calling, and annotation were 
performed as described [261]   using data from the UCSC GoldenPath database 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/), the ESP6500 dataset 
from the Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA 
(http://evs.gs.washington.edu/EVS/) (accessed August 2012), the Institute of Systems 
Biology KAVIAR (Known VARiants) database (http://db.systemsbiology.net/kaviar/) 
[269], the National Center for Biotechnology Information dbSNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) [270] build 137, and the 1000 Genomes 
(http://www.1000genomes.org/);  [271]. Variants were also annotated for their presence 
in an in-house database consisting of over 1400 whole exomes that were sequenced in 
parallel with our DC families.  Variants within each family were filtered and categorized 
as indicated in Table 2.4. 
Ion semiconductor sequencing 
Validation of exome sequencing findings in the NCI-275 family was performed by 
sequencing the entire genomic locus surrounding TPP1 (chr16:67690393-67695778).  
A targeted, multiplex PCR primer panel (Table 2.6) was designed using the custom Ion 
AmpliSeq Designer v3.0 (Life Technologies, Carlsbad, CA, USA).  The primer panel 
covered 95.85% of the ACD gene, including introns and up- and down-stream 
sequence.  Average amplicon size was 224bp.  DNA was amplified using this custom 
AmpliSeq primer pool, and libraries were prepared following the manufacturer’s Ion 
AmpliSeq Library Preparation protocol (Life Technologies, Carlsbad, CA, USA).  
Individual samples were barcoded, pooled, templated, and sequenced on the Ion 
Torrent PGM Sequencer using the Ion PGM Template OT2 200 and Ion PGM 
Sequencing 200v2 kits per manufacturer’s instructions.  Mean read length after 
sequencing was 140bp.  
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Sanger sequencing 
EBV-transformed lymphoblastoid cells derived from family members were 
cultured in IMDM media containing 20% FBS and 1% L-alanyl-L-glutamine.  Fibroblast 
cells derived from the family members were cultured in DMEM containing 10% FBS.  
Genomic DNA was isolated from the above cells with PUREgene Blood Core Kit B 
using the manufacturer’s instructions (Qiagen).  The genomic region of interest was 
amplified by PCR with sequence-specific primers (Table 2.6).  PCR products were 
sequenced by the University of Michigan DNA Sequencing Core and resulting data 
were analyzed using the Sequencher 5.1 DNA sequence analysis software (Gene 
Codes Corporation, Ann Arbor, MI). 
In silico analysis 
 PolyPhen-2 [272] (http://genetics.bwh.harvard.edu/pph2), SIFT [273] 
(http://sift.jcvi.org), PROVEAN [274] (http://provean.jcvi.org), MutationAssessor [275] 
(http://mutationassessor.org), MutationTaster [276] (http://mutationtaster.org), and 
FATHMM [277] (http://fathmm.biocompute.org.uk), and CADD [278] were used to 
predict the severity of TPP1 mutations.  Multiple sequence alignments were generated 
for homologous TPP1 protein sequences using COBALT [279] (http://www.st-
va.ncbi.nlm.nih.gov/tools/cobalt) and viewed in Jalview [280](www.jalview.org) to 
evaluate conservation.  Alignments were generated with proteins NP_001075955.1 
(Homo sapiens), EPQ14055.1 (Myotis brandtii), AAI49588.1 (Bos taurus), ELR55817.1 
(Bos mutus), EHH31762.1 (Macaca mulatta), NP_001032270.1 (Rattus norvegicus), 
NP_001012656.1 (Mus musculus), EGV97050.1 (Cricetulus griseus), ELV12230.1 
(Tupaia chinensis), EHB17028.1 (Heterocephalus glaber), ELK14507.1 (Pteropus 
alecto), ELK25602.1 (Myotis davidii), EPY84197.1 (Camelus ferus), NP_001089068.1 
(Xenopus laevis), and NP_001124265.1 (Danio rerio). 
Site-directed mutagenesis 
Oligonucleotides for site-directed mutagenesis were purchased from Integrated 
DNA Technologies (Coralville, IA).  Indicated variants for expression in cultured human 
cells were introduced into the ACD gene using fully complementary mutagenic primers 
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(QuickChange® Site-Directed Mutagenesis Kit; Agilent Technologies, Santa Clara, CA).  
The p3X-FLAG-TPP1-CMV plasmid was used as the template in the PCR reaction.  The 
ACD genes in the mutant plasmids were sequenced completely to confirm the presence 
of the intended mutation and to exclude the acquisition of unwanted nucleotide 
changes. 
Expression and purification of recombinant proteins 
Purified wild-type and K170∆ Smt3-TPP1-N fusion proteins were obtained upon 
lysis of isopropyl β-d-thiogalactopyranoside-induced BL21(DE3) cells after nickel–
agarose chromatography, treatment with Ulp1 protease (MTA with Cornell University for 
pUlp1 vector) to cleave the Smt3 tag, and size exclusion chromatography (Superdex 75, 
GE Life Sciences) as reported previously [69]. The full-length human POT1 gene was 
cloned into a His-Sumostar-containing baculoviral expression vector (Life Sensors) and 
expressed in baculovirus-infected High Five cells (Life Technologies) using vendor 
recommendations. POT1 protein was purified from these insect cell lysates using 
nickel–agarose chromatography, treatment with SUMOstar protease (Life Sensors), 
anion exchange (HiTrap Q HP, GE Life Sciences), and size exclusion chromatography 
(Superdex 200, GE Life Sciences).   
HeLa and HEK293T cell culture 
A clonal HeLa cell line called HeLa-EM2-11ht [81] was used for all transient 
transfection experiments reported here involving HeLa cells. HeLa-EM2-11ht was 
obtained from Tet Systems Holdings. KG upon signing an MTA. HeLa1.2.11 cells were 
used only in the telomere ChIP experiments. Both HeLa cell lines and the HEK293T 
cells were cultured at 37°C in the presence of 5% CO2; they were propagated in growth 
medium containing DMEM, 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 
U/mL penicillin, and 100 µg/mL streptomycin. Doxycycline was added to a final 
concentration of 200 ng/mL for expression of the human POT1 (or TIN2) gene that is 
driven by a tetracycline-inducible promoter from the p3X-Flag-POT1-BI4 (or p3X-Flag-
TIN2-BI4) plasmid in HeLa-EM2-11ht cells [81].  
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Culture and manipulation of EBV-transformed lymphoblasts from proband and 
family members 
EBV-transformed lymphoblastoid cells derived from family members were 
cultured in IMDM medium containing 20% FBS and 1% L-alanyl-L-glutamine. They were 
centrifuged at 1200 rpm for 3 min and washed with 1× PBS to pellet the cells. The cells 
were then resuspended in 1% BSA–PBS to a final concentration of ∼200 cells per 
microliter. To prepare slides for FISH analysis, a cytocentrifuge (Rotofix 32A, Hettich 
Lab Technology) was used. One-hundred microliters of cell suspension was aliquoted 
into cytocentrifuge funnels and centrifuged at 800 rpm for 3 min. After dissembling the 
centrifugation setup, a hydrophobic circle was drawn on each slide around the smear 
using a hydrophobic pen. Cells were fixed with 4% formaldehyde in PBS for 8 min and 
stored at −20°C. Slides were thawed to room temperate immediately prior to FISH 
experiments. 
Immunofluorescence and Fluorescent In Situ Hybridization (IF/FISH) 
IF/FISH experiments to measure telomerase recruitment were performed using 
published protocols [81]. Briefly, confluent six-well plates containing HeLa-EM2-11ht 
cells were transfected with 1 µg of p3X-Flag-TPP1-CMV (wild-type or indicated mutant) 
plasmid [265], 1 µg of TERT-cDNA6/myc-HisC plasmid, and 3 µg of phTR-Bluescript II 
SK(+) plasmid using Lipofectamine 2000 (Life Technologies) following the 
manufacturer’s recommendations. Three days post-transfection, cells were fixed with 
4% formaldehyde in PBS for 8 min. After fixative removal, the cells were permeabilized 
with PBS containing 0.5% Triton X-100 (PBS-T), blocked in PBS-T containing nuclease-
free 3% BSA, and incubated with mouse monoclonal anti-Flag M2 (1:500; F1804, 
Sigma) and rabbit polyclonal anti-coilin (1:100; sc-32860, Santa Cruz Biotechnology ) in 
PBS-T containing nuclease-free 3% BSA for 1 h. The cells were then washed in PBS 
and incubated with Alexa Fluor 488-conjugated anti-mouse IgG (Life Technologies) and 
Alexa Fluor 568-conjugated anti-rabbit IgG (Life Technologies) diluted 1:500 in PBS-T 
containing nuclease-free 3% BSA for 30 min in the dark. The cells were washed in PBS 
and fixed again in 4% formaldehyde in PBS for 10 min at room temperature. The fixative 
was removed, and the cells were incubated successively in 70%, 95%, and 100% 
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ethanol. Upon removal of ethanol, cells were rehydrated in 50% formamide in 2× SSC 
buffer for 5 min. The coverslips were prehybridized with solution containing 100 mg/mL 
dextran sulfate, 0.125 mg/mL Escherichia coli tRNA, 0.5 mg/mL salmon sperm DNA, 1 
mg/mL nuclease-free BSA, 1 mM vanadyl ribonucleoside complexes, and 50% 
formamide in 2× SSC for 1 h at 37°C in a humidified chamber. Prehybridization buffer 
was then removed, and the coverslips were incubated overnight at 37°C in a dark 
humidified chamber in hybridization solution containing a mixture of three Cy5-
conjugated TR probes (90 ng of each probe per coverslip) [281]. The next morning, the 
cells were washed with 50% formamide in 2× SSC followed by PBS, and the coverslips 
were mounted on microscope slides using ProLong Gold anti-fade reagent containing 
DAPI (Life Technologies). The coverslips were sealed using transparent nail polish and 
stored at −20°C. Imaging was performed using a laser-scanning confocal microscope 
(SP5, Leica) and a 100× oil objective. Images were processed using ImageJ and Adobe 
Photoshop. Pseudocolored representative cells are shown in figure panels. Mean and 
standard deviations of three experiments, each involving 100–150 telomeric foci, were 
plotted for each TPP1 construct. For IF experiments to detect RAP1, rabbit polyclonal 
anti-RAP1 (1:500; NB100-292, Novus Biologicals) was used. Telomere FISH of EBV-
transformed lymphoblasts was performed with a red fluorescence probe: Cy3-OO-
CCCTAACCCTAACCCTAA-3′ (Bio-Synthesis, Inc.).  
Telomerase activity assays 
Both versions of the direct primer extension experiments to measure telomerase 
processivity shown in Figures 2.9 and 2.10 were based on published protocols [81]. 
Briefly, for the experiments shown in Figures 2.9A, C, D, and 2.10, HeLa-EM2-11ht cells 
grown in the wells of a six-well plate were transfected with the indicated plasmid DNA 
using Lipofectamine 2000 (Life Technologies) using the manufacturer’s 
recommendations. One microgram of TERT-cDNA6/myc-HisC, 3 µg of phTR-Bluescript 
II SK(+), 1.5 µg of p3X-Flag-POT1-BI4, and 0.5–0.7 µg of p3X-Flag-TPP1-CMV (wild 
type or mutant) were added per transfection. In control transfections where POT1 and 
TPP1 were omitted, 2 µg of empty vector was included. Two days post-transfection, the 
cells were trypsinized, washed with PBS, lysed in 100 µL of CHAPS lysis buffer [70], 
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and centrifuged (13,600 rpm for 10 min) to remove cell debris. The clarified lysates were 
flash-frozen in liquid nitrogen and stored at −80°C. Telomerase reactions were carried 
out in 20-µL volumes containing 50 mM Tris-Cl (pH 8.0), 30 mM KCl, 1 mM spermidine, 
1 mM MgCl2, 5 mM β-mercaptoethanol, 1 µM primer a5 (TTAGGGTTAGCGTTAGGG), 
500 µM dATP, 500 µM dTTP, 2.92 µM unlabeled dGTP, 0.33 µM radiolabeled dGTP 
(3000 Ci/mmol), and 3 µL of HeLa-EM2-11ht cell extracts for 60 min at 30°C. Reactions 
were stopped with buffer containing 100 µL of 3.6 M ammonium acetate and 20 µg of 
glycogen and precipitated with ethanol. The pellets were resuspended in 10 µL of H2O 
and 10 µL of loading buffer containing 95% formamide, heated for 10 min at 95°C, and 
resolved on a 10% acrylamide, 7M urea, and 1× TBE sequencing gel. Gels were dried 
and imaged on a PhosphorImager (Storm; GE), and the data were analyzed using 
Imagequant TL (GE Life Sciences) software. Processivity calculations were performed 
exactly as described previously [70]. Briefly, the intensities of individual bands in the 
ladder generated by telomerase activity in each lane were quantified and divided by the 
number of added guanosine nucleotides. For a given band n, the fraction left behind 
(FLB), which is the sum of counts for repeats (1 − n) divided by the total counts in the 
lane, was calculated. Next, ln(1 − FLB) was plotted against repeat number for each 
lane, and the plot was fit with a linear regression equation with slope m. The 
processivity value, which is plotted in Figures 2.9C and E, equals −0.693/m.  
For telomerase activity assays shown in Figures 2.9B, E, and F, HEK293T cells 
were transfected with TERT-cDNA6/myc-HisC and phTR-Bluescript II SK(+) plasmids 
as described for HeLa, but plasmids encoding POT1 and TPP1 were omitted. 
Telomerase extracts were prepared exactly as detailed above for HeLa lysates. The 
telomerase assay was also performed exactly as above with the exception that purified 
POT1 and TPP1-N proteins (wild type or K170Δ) were preincubated with the DNA 
primer for 5 min on ice prior to addition of the telomerase extract. All subsequent steps 
of the assay, including electrophoresis, gel-drying, imaging, and processivity analyses, 
were performed exactly as detailed above for telomerase assays with HeLa extracts. 
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Co-immunoprecipitation (Co-IP) assay 
HeLa-EM2-11ht cells were seeded and transfected with 1 µg each of plasmids 
encoding Flag-TIN2 and wild-type or mutant Flag-TPP1. After 24 h of transfection, cells 
were washed with PBS, dislodged with a cell scraper using 400 µL of ice-cold lysis 
buffer (50 mM Tris-Cl at pH 7.4, 20% glycerol, 1 mM EDTA, 150 mM NaCl, 0.5% Triton 
X-100, 0.02% SDS, 1 mM dithiothreitol, 2 mM phenylmethylsulfonyl fluoride, complete 
protease inhibitor cocktail [Roch]), and kept on ice. After 5 min, 20 µL of 5 M NaCl was 
added and mixed. After another 5 min on ice, 420 µL of ice-cold water was added and 
mixed before immediate centrifugation (13,600 rpm for 10 min). Supernatants were 
collected and used directly for immunoprecipitation. Lysate (40 µL) added to 40 µL of 4× 
SDS gel loading buffer was kept aside for analysis of “input” samples. Five microliters of 
anti-TIN2 antibody was added, followed by incubation overnight at 4°C. Fifty microliters 
of protein A/G sepharose beads (Pierce; Thermo Scientific) preincubated with 100 
mg/mL BSA in PBS was added, and samples were mixed with rocking on a nutator for 2 
h at 4°C. Beads were washed three times with 1:1 diluted lysis buffer, and proteins were 
eluted by adding an equal volume of 2× SDS gel loading buffer for analysis of “bead” 
samples. All “input” (10 µL) and “bead” (15 µL) samples were heated for 12–14 min at 
90°C and analyzed by SDS-PAGE and immunoblotting using HRP-conjugated anti-Flag 
antibody. The fraction of TIN2 that is bound by TPP1 (normalized against the ratio of 
wild-type TPP1: wild-type TIN2) was determined by quantification of the 
chemiluminescence signal using a ChemiDoc MP gel imager (Bio-Rad) and subsequent 
analysis using AlphaView software (ProteinSimple). Results from four independent 
experiments were used to generate means and standard deviations. 
For Co-IP assays in Figure 2.5, HeLa-EM2-11ht cells were seeded and 
transfected with 1 µg of TERT-cDNA6/myc-HisC, 3 µg of phTR-Bluescript II SK(+), 1.5 
µg of p3X-Flag-POT1-BI4, and 1 µg of p3X-Flag-TPP1-CMV (wild type or mutant) were 
added per transfection. In control transfections where TPP1 were omitted, 2 µg of empty 
vector was included. Lysates were prepared exactly as detailed above. Lysate (40 µL) 
added to 40 µL of 4× SDS gel loading buffer was kept aside for analysis of “input” 
samples. Fifty microliters of anti-FLAG M2-agarose (Sigma) preincubated with 100 
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mg/mL BSA in PBS was added in the presences of a5 (TTAGGGTTAGCGTTAGGG) 
oligonucleotide, and samples were mixed with rocking on a nutator for 2 h at 4°C.  
Beads were washed three times with 1:1 diluted lysis buffer, and proteins were eluted 
by adding an equal volume of 2× SDS gel loading buffer for analysis of “bead” samples. 
All “input” and “bead” samples were heated for 12–14 min at 90°C and analyzed by 
SDS-PAGE and immunoblotting using rabbit monoclonal antibody TERT(C-term) 
antibody (Abcam) or HRP-conjugated anti-Flag antibody. Horse-radish peroxidase-
conjugated goat antiboesd against rabbit (Santa Cruz Biotechnology) was used to 
reveal the primary antibody using chemiluminescence detection by ECL plus reagents 
(GE Healthcare Life Sciences). Quantification was performed using a ChemiDoc MP gel 
imager (Bio-Rad) and subsequent analysis using AlphaView software (ProteinSimple).  
Telomere ChIP 
HeLa1.2.11 cells were transfected with the p3X-Flag-TPP1-CMV (either wild type 
or P491T) as detailed above for HeLa-EM2-11ht. Transfected cells were processed for 
ChIP as described previously [282]. Following cell lysis, 15% of the lysates were kept 
aside to serve as “input” samples. Immunoprecipitation on the remaining 85% of the 
lysates was performed by addition of 4 µg of mouse anti-TRF2 4A794.15 (NB100-
56506, Novus Biological) and 4 µg of monoclonal anti-ACD (H00065057-M02, Abnova) 
antibodies. Hybridization was performed in Church buffer (0.5 M sodium phosphate 
buffer at pH 7.2, 1% BSA, 1 mM EDTA, 7% SDS) as described previously (de Lange 
1992) using 32P-labeled (TTAGGG)4 or an oligonucleotide probe to detect Alu repeats 
[78]. Following hybridization, membranes were washed to reduce nonspecific binding of 
the probe, imaged using a PhosphorImager (Storm, GE Life Sciences), and quantified 
using ImageJ software. The percentage of input DNA that was pulled down was plotted.  
Structural modeling 
The Web-based Swiss Model software (http://swissmodel.expasy.org; [283]) was 
used to create a homology model for TPP1-OB K170Δ and TPP1-OB Q205R based on 
the crystal structure of TPP1-OB wild type (PDB: 2I46). The homology model was 
subjected to energy minimization using the crystallography and NMR (nuclear magnetic 
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resonance) system (CNS) program (http://cns-online.org/v1.3; [284]) to furnish the 
model displayed in Figure 2.12.  
RESULTS 
Clinical characterization 
The male proband NCI-275-1 is an identical twin born at 29-week gestation with 
IUGR. Clinical features consistent with HH were noted during the first year of life and 
included microcephaly, cerebellar hypoplasia, developmental delay, oral leukoplakia, 
nail dystrophy, and esophageal stenosis (Table 2.1). By age 20 mo, the proband 
required regular platelet and red blood cell transfusions for bone marrow failure. 
Fanconi anemia and Shwachman-Diamond syndrome were excluded based on a 
normal chromosomal breakage test and the absence of mutations in SBDS 
(Shwachman-Bodian-Diamond syndrome) gene, respectively. Despite extremely short 
blood leukocyte telomere length, as demonstrated by flow cytometry with FISH (Figure 
2.4A) and by FISH/confocal microscopy of EBV-transformed lymphoblasts (Figure 
2.4B), sequencing did not identify mutations in any of the nine known DC-associated 
genes. The proband underwent successful matched unrelated hematopoietic stem cell 
transplantation at 3 yr of age. 
The proband’s identical twin, NCI-275-2, was also affected by IUGR and died at 
4 mo from complications of pertussis. The proband’s older sister, NCI-275-3, is healthy 
and has no clinical features of DC but has very short telomeres (Figure 2.4A). The 
proband has two healthy younger sisters who are identical twins, NCI-275-4 and NCI-
275-5, with telomeres at the first percentile (Figure 2.4A, B). Although the twins’ 
telomeres are at the low end of the normal range, they do not meet the stringent criteria 
for a DC diagnosis (three out of four leukocyte subsets, excluding granuloctyes, below 
the first percentile) [259]. Both parents (father, NCI-275-6, and mother, NCI-275-7) are 
healthy, although the father has very short telomeres, premature gray hair, and minor 
dental abnormalities (Figure 2.3 and 2.4A; Table 2.1).  
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Sequence analysis 
DNA from the proband (NCI-275-1), his older sister (NCI-275-3), and both 
parents (NCI-275-6 and NCI-275-7) (Figure 2.3) was analyzed by whole-exome 
sequencing, resulting in ∼300,000 reported variants. We used a custom filtering 
algorithm to identify likely causal variants. Based on data from the National Institutes of 
Health Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP), the 
1000 Genomes Project, and an in-house database of 1400 exomes, we identified the 
rarest variants in accordance with the low prevalence of DC (Table 2.4). We further 
filtered variants by family structure using telomere length as the phenotype of interest to 
minimize the effect of variable expressivity: Because the proband (NCI-275-1), older 
sister (NCI-275-3), and father (NCI-275-6) all have short telomeres, we hypothesized 
that they must share a contributing variant despite the fact that they are not equally 
affected clinically. This resulted in a list of 40 variants (Table 2.5), only one of which was 
in a telomere biology gene: ACD (ACD), chr16:67693689–67693691delCTT (genomic 
coordinates correspond to GRCh37/hg19). A second ACD variant, chr16:67691750G>T, 
shared by the proband (NCI-275-1) and mother (NCI-275-7), was also present. The 
presence or absence of each of the two variants was validated in all six family members 
by both ion semiconductor sequencing of the entire gene locus and Sanger sequencing 
of the region around the mutations; the healthy twins (NCI-275-4 and NCI-275-5) carry 
neither mutation. The healthy paternal grandmother is also wild type at both of these 
loci; DNA was not available on any other family members.  
The 3-base-pair (3-bp) deletion results in an in-frame deletion of a single amino 
acid, K170 (based on NM_001082486.1/NP_001075955.1). This residue is located in 
the OB fold of TPP1 (Figure 2.2A; [69]). The deletion affects a conserved solvent-
accessible charged loop, a likely site of molecular interaction. This is supported by 
reports describing the TEL patch of TPP1 (Figure 2.2A), a cluster of residues 
encompassing this deletion that mediates interactions required for telomerase 
recruitment and telomerase processivity [79, 81]. K170 is implicated in the interaction 
between TPP1 and telomerase [79], and mutation of adjacent amino acids (E169 and 
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E171) has been shown to severely impede both telomerase recruitment and 
processivity [81]. Deletion of K170, a residue that is strictly conserved in mammals 
(Figure 2.2B), is predicted to be deleterious by in silico algorithms (Table 2.2). This 
mutation is not reported in National Center for Biotechnology Information Single 
Nucleotide database build 137 (dbSNP 137), the ESP database, or the 1000 Genomes 
Project and is not present in our internal non-DC population. 
The missense variant chr16:67691750 G>T results in the replacement of a 
proline by a threonine at amino acid position 491 (P491T; 
NM_001082486.1/NP_001075955.1). The P491T mutation resides in the C-terminal 
TIN2-interacting domain of TPP1 (Figure 2.2A); this interaction is required for TPP1 
localization (and hence telomerase recruitment) to telomeres [59]. P491 is also well 
conserved in mammals (Figure 2.2B), and four of six in silico prediction algorithms list 
this mutation as deleterious (Table 2.2). This variant is listed in dbSNP as rs201441120 
and is present in the ESP database (n = 6496 individuals) with a MAF of 0.0002; 
however, it is not present in the 1000 Genomes Project or our internal non-DC 
population (total n ≈ 9900 individuals).  
TPP1-Telomerase Interaction 
To examine the effect of deletion of K170 on the interaction of TPP1 and 
telomerase, we performed Co-IP assays (Figure 2.5). HeLa cells were transiently 
transfected with plasmids encoding TERT, TR, and Flag-tagged POT1 and TPP1 (wild 
type, K170∆) and immunoprecipitated with Flag beads. We did not observe a significant 
reduction in the interaction of TPP1 and TERT in the presence of K170Δ. These studies 
demonstrated that K170Δ does not cause a significant defect in the interaction between 
TPP1 and telomerase. 
Telomerase recruitment 
To test the effect of deletion of K170 on telomerase recruitment, we conducted 
an IF/FISH-based telomerase recruitment assay. HeLa cells transiently transfected with 
plasmids encoding TERT, TR, and Flag-tagged TPP1 (wild type, K170∆, P491T) were 
fixed and stained/probed for Flag, TR, and coilin (a marker of Cajal bodies). Flag-tagged 
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TPP1, TPP1-K170∆, TPP1-P491T were visualized as punctate foci (Figure 2.6A). As in 
previous studies [81], the Flag foci observed here represent telomeres insofar as they 
colocalize with the shelterin component RAP1 (Figure 2.7). FISH probes for TR 
indicated the localization of telomerase in the same nuclei. As expected, we observed 
that a large fraction of the TR foci localized to telomeres in the presence of wild-type 
TPP1 (Figure 2.6A). Quantification of data collected from triplicate experiments for each 
TPP1 construct revealed that 54% of all telomeric foci in wild-type cells contain TR foci 
(Figure 2.6B), confirming efficient recruitment of telomerase to telomeres by wild-type 
TPP1. In addition, we observed coilin (Figure 2.6A) colocalizing with both telomerase 
and telomeres in structures referred to as neo-Cajal bodies, consistent with previous 
observations [79]. 
In sharp contrast to cells expressing wild-type TPP1 but akin to TEL patch 
mutant cells [81], the TR foci in cells expressing TPP1-K170Δ rarely localize at 
telomeres; only 3% of Flag-TPP1-K170Δ foci colocalize with TR foci (Figure 2.6B). TR 
foci in TPP1-K170Δ cells maintained their colocalization with coilin, suggesting that the 
K170∆ mutation interferes with recruitment of telomerase from Cajal bodies to 
telomeres.  
Next, we measured telomerase recruitment in HeLa cells transiently expressing 
TPP1-P491T, the maternally inherited heterozygous mutation in the proband. TR 
efficiently colocalized with telomeres in the presence of TPP1-P491T (Figure 2.6A). 
Quantification revealed that 65% of all telomeric foci in TPP1-P491T-expressing cells 
contain TR foci (Figure 2.6B), suggesting that the P491T mutation does not severely 
interfere with the interaction of telomerase and Flag-tagged TPP1-P491T at telomeres.  
Previously our collaborator at NCI identified another variant in ACD in a different 
family with DC using a candidate gene strategy, Q205R. The patient also harbors a 
TERC mutation in close vicinity to the RNA templating region. Q205 is also located in 
the OB-fold domain but it is far from the TEL patch; thus, Q205R is unlikely to be the 
cause of DC in this patient. However, it was still of interest to functionally characterize 
this mutation. Therefore, we also measured telomerase recruitment in HeLa cells 
transiently expressing TPP1-Q205R.  We observed that TR colocalized with telomeres 
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in the presence of TPP1-Q205R (Figure 2.8A). Although quantification revealed that 
29% of all telomeric foci in TPP1-Q205R-expressing cells contain TR foci (Figure 2.8B), 
the difference between WT-TPP1 and Q205R-TPP1 expressing cells was not significant 
(P= 0.09).   
Telomerase processivity 
The TEL patch of TPP1 has also been shown to stimulate telomerase 
processivity [81], enabling telomerase to synthesize long DNA products containing 
multiple telomeric repeats. To test the effect of TPP1-K170Δ on telomerase 
processivity, direct telomerase primer extension assays were performed using two 
methods. The first method involves using lysates of HeLa cells expressing Flag-TERT, 
TR, Flag-POT1, and Flag-TPP1 (wild type or mutant) as reported previously [81]. 
Although the use of HeLa extracts provides limiting amounts of Flag-POT1 and Flag-
TPP1 for the telomerase activity assay, the proteins are coexpressed with telomerase in 
human cells, more closely recapitulating what occurs in vivo. Compared with the 
untransfected control, transfection of wild-type TPP1 resulted in an increase in 
processivity [69], indicated by the appearance of higher-molecular-weight (slower-
migrating) products (Figure 2.9A). However, the deletion of K170 led to the 
disappearance of the slowest-migrating bands observed with wild-type TPP1 (Figure 
2.9A). Quantification of the data from multiple experiments further indicates a 
telomerase processivity defect in the presence of TPP1-K170Δ (Figure 2.9C). The 
deleterious effect of TPP1-K170Δwas not a result of varying protein levels, as Flag-
TERT, Flag-POT1, and Flag-TPP1 protein levels were comparable in all cell lines tested 
(Figure 2.9D). The P491T mutation does not cause a significant defect in telomerase 
processivity (Figure 2.10), consistent with the nonessential nature of the TIN2-binding 
domain for stimulation of telomerase processivity [69].  
We repeated the analysis of telomerase processivity using purified, recombinant 
POT1 and TPP1-N (a TPP1 construct that binds POT1 as well as telomerase) [69]. 
These proteins were added at high concentrations (see the Materials and Methods) to 
lysates from HEK293T cells transiently overexpressing telomerase (supertelomerase); 
the increased POT1/TPP1 concentrations allow for a larger stimulation of telomerase 
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processivity [70]. Using this approach, we saw the characteristic threefold to fourfold 
increase in telomerase processivity in the presence of the POT1–TPP1 complex 
containing wild-type TPP1-N but not with POT1–TPP1-N (K170Δ) (Figure 2.9B, E). 
Because both TPP1-N (wild type) and TPP1-N (K170∆) proteins were purified to similar 
levels (Figure 2.9F) and were added to the assay at the same concentrations, we 
conclude that the TPP1-K170∆ mutation reduces the ability of POT–TPP1 to stimulate 
telomerase processivity.  
TPP1–TIN2 interaction 
Because the P491T mutation resides in the TIN2-interacting domain of TPP1, 
this mutation may affect TIN2–TPP1 binding. To assess the interaction between TIN2 
and mutant TPP1, we performed Co-IP assays (Figure 2.11A, B). Whereas wild-type 
TPP1 and TPP1-K170Δ efficiently precipitated with TIN2, TPP1-P491T showed a 
modest (approximately twofold) reduction in TIN2 association. 
Disruption of the TIN2–TPP1 interaction can indirectly cause a reduction in 
telomerase recruitment to telomeres; however, we did not see evidence of this in the 
telomerase recruitment assay (Figure 2.6). To monitor the effect of the P491T mutation 
with regard to TPP1 recruitment to telomeres, we conducted telomere ChIP 
experiments. Our results show that TPP1 (as well as TRF2, a positive control) binding 
to telomeres is unaffected by the P491T mutation, at least under the conditions of this 
assay (Figure 2.11C, D).  
TPP1 structural modeling 
To gain insight into the structural implications of this deletion, we constructed a 
model for TPP1-OB lacking K170 based on the TPP1-OB wild-type crystal structure 
(Protein Data Bank [PDB]: 2I46) using homology modeling and energy minimization 
(see the Materials and Methods for details). The crystal structure for the wild-type 
protein (Figure 2.12A, B; [69]) reveals that while E168, E169, and E171 amino acid side 
chains are surface-exposed and available for binding telomerase, K170 is buried and 
directed toward the core of the wild-type protein. Strikingly, deletion of K170 results in a 
structural model in which the amino acid side chain of E169 is withdrawn from the 
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surface and buried in the core of the protein structure (Figure 2.12A). In comparison, a 
model of the missense mutation K170A does not exhibit any gross conformational 
changes in E168, E169, or E171 (data not shown), suggesting a structural basis for the 
modest effect of K170A on telomerase recruitment [79]. In summary, our structural 
modeling suggests that deletion of K170 occludes E169 from telomerase binding and 
reduces the extent of the acidic patch on TPP1-OB, thereby compromising telomerase 
recruitment and processivity. On the other hand, Q205R does not exhibit a significant 
change in the structure of TPP1-OB (Figure 2.12B), supporting the lack of a recruitment 
defect in the presence of TPP1-Q205R (Figure 2.8A, B). 
DISCUSSION 
Here we describe an individual affected by the severe DC variant HH who 
harbors two ACD mutations affecting two distinct TPP1 domains. TPP1 interacts with 
both POT1 and TIN2, forming a bridge between the ssDNA-binding and dsDNA-binding 
components of the shelterin complex, thereby enabling proper chromosome end 
protection [264]. TPP1 recruits telomerase via its TEL patch, allowing efficient extension 
of chromosome ends in actively replicating cells. The mutation affecting the TEL patch, 
K170Δ, abrogates telomerase recruitment and reduces telomerase enzymatic 
processivity. The TIN2-binding domain mutation P491T showed a modest reduction in 
the interaction between TPP1 and TIN2 but did not significantly affect telomerase 
recruitment or processivity.  
To understand the functional significance of the K170Δ mutation of TPP1, we 
performed telomerase recruitment assays using IF/FISH (Figure 2.6) and telomerase 
activity assays (Figure 2.9). Our results demonstrated that K170Δ compromises both 
telomerase recruitment and processivity. K170 is located adjacent to the TEL patch 
amino acids E168, E169, and E171, which form an acidic patch on the TPP1-OB 
structure that is critical for telomerase function. Our structural modeling suggests that 
deletion of K170 occludes E169 from telomerase binding and reduces the extent of the 
acidic patch on TPP1-OB, which compromises telomerase recruitment and processivity 
(Figure 2.12). However, in the absence of a crystal structure for K170Δ, we cannot rule 
out additional disruptive changes in the TEL patch caused by deletion of K170.  
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P491 resides in the TIN2-binding domain of TPP1, which is important for 
recruiting TPP1 (and hence telomerase) to telomeres but is dispensable for telomerase 
processivity. As expected, the P491T amino acid change did not result in a significant 
reduction in telomerase processivity (Figure 2.10) or interaction with telomerase at 
telomeres (Figure 2.6). However, we observed that P491T significantly inhibited the 
interaction between TIN2 and TPP1 (Figure 2.11A, B). The physiological relevance of 
this partial TIN2-binding defect is unclear; TPP1-P491T is present at telomeres at wild-
type levels by ChIP, suggesting that the reduction in TIN2 binding is not sufficient to 
impact TPP1 recruitment in vivo (Figure Figure 2.11C, D). Because our analysis of 
P491T was done using transient transfections, it is possible that subtle phenotypes 
were masked via overexpression. Additionally, our analyses assessed the defects of 
TPP1-K170Δ and TPP1-P491T individually, while the severely affected proband harbors 
both variants; it is possible that the combination of these two alleles is more deleterious 
than the presence of either single allele. Therefore, we cannot exclude the possibility 
that TPP1-P491T is a disease modifier in the proband, although any potential 
contribution of P491T to the disease in the proband is likely minor compared with that of 
the K170∆ mutation.  
The data indicating that TPP1-K170Δ severely compromises telomerase 
recruitment and processivity while TPP1-P491T has no significant effect on telomerase 
recruitment are consistent with the phenotypes associated with the family members 
having one or both of these mutations. The heterozygous carriers of TPP1-K170Δ (the 
father and older sister), while clinically healthy at this time, are affected on a molecular 
level: Their telomeres are below the first percentile for age, an important consideration 
for family planning and potential bone marrow donation to affected relatives. The 
mother, a carrier of P491T, is currently unaffected and has telomeres between the 10th 
and 50th percentiles, suggesting that P491T does not cause a significant change in 
telomere length; this is consistent with the minimal defects that we observed for this 
allele. The healthy twins do not harbor either TPP1 mutation, although their telomeres 
are at the low end of the normal range for their age; this is presumably a consequence 
of inheritance from at least one parent with very short telomeres [285]. The proband, the 
most severely affected individual in this family, is also the only one to harbor both 
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K170Δ and P491T. The two TPP1 mutations may have a synergistic relationship in 
which a modest defect with the P491T allele is magnified in an environment where 
TPP1 is already deficient due to the K170Δ mutation. Alternatively, a minimal P491T 
defect may be sufficient to drop TPP1 function below a certain functional threshold in 
the context of the K170Δ mutation, resulting in disease. Characterization of endogenous 
TPP1 expression and function in cells derived from the proband and his family members 
will likely provide further insight into the precise contribution of P491T to telomere 
maintenance and HH. We cannot rule out the presence of other disease-modifying 
factors, genetic anticipation, or incomplete penetrance in contributing to development of 
HH in the proband but not in other K170Δ carriers.  
TPP1 has previously been implicated in the proper functioning of the tissues 
most affected by DC and HH. In mice, the adrenocortical dysplasia (acd) mutant 
phenotype, caused by a hypomorphic allele of Tpp1, includes a number of features of 
DC, including growth retardation, skin hyperpigmentation, and sparse hair [84]. In 
caddition, mouse hematopoietic stem cells homozygous for the acd allele are 
profoundly defective in transplantation assays, and complete inactivation of Tpp1 results 
in severe depletion of hematopoietic progenitors [286]. Deletion of Tpp1 in the epithelial 
tissue leads to perinatal death, severe skin hyperpigmentation, defective hair follicle 
morphogenesis, and epithelial dysplasia [287]. While the above studies do not 
necessarily implicate the TEL patch of TPP1 in stem cell function, a very recent study 
using genetic engineering of human embryonic stem cells has revealed that deletion of 
a segment of the TEL patch that includes K170 results in telomere shortening and 
decreased cell viability [82]. These reports and our current study together suggest that 
reduced telomerase recruitment and processivity caused by perturbation of the TEL 
patch of TPP1 result in reduced stem cell function, which provides a mechanism 
explaining the characteristic mucocutaneous and hematopoietic features of DC.  
TPP1 is not the first shelterin component implicated in DC; mutations in exon 6a 
of TINF2 result in DC, HH, and the related telomere biology disorders of aplastic anemia 
and Revesz syndrome [58-60, 208]. However, TINF2 DC mutations, which do not affect 
interaction of TIN2 with any of its shelterin-binding partners, cause telomere shortening 
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via mechanisms that involve both telomerase-dependent and telomerase-independent 
pathways. In contrast, the deletion in the TEL patch of TPP1 described here provides a 
more direct model for telomere length shortening resulting from diminished telomerase 
recruitment to telomeres and reduced telomerase enzymatic processivity. In summary, 
this is the first report of DC/HH caused by germline mutations in TPP1 and further 
illustrates the importance of this shelterin component in human telomere biology.  
 
 
 
 
 
 
 
   66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Schematic diagram of telomerase recruitment from Cajal 
bodies to telomeres coated with the shelterin complex. The RNA 
component of telomerase is indicated as TR, also known as TERC. 
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Figure 2.2: The affected TPP1 amino acids in ACD/TPP1. (A) The domain 
structure of TPP1 is depicted. The TEL patch is highlighted in yellow with K170 in 
red. The location of the P491T variant is also depicted on the domain diagram. (B) 
Sequence alignment surrounding the affected amino acids, showing their location 
in highly conserved regions. 
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Figure 2.3: The pedigree for NCI-275 showing first-degree relatives of 
the proband.  The proband is indicated by an arrowhead. A diagnosis of HH 
is indicated by a filled left half, and telomeres below the first percentile are 
indicated with a filled upper right quadrant. ACD genotypes are shown below 
each symbol. 
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Figure 2.4: Telomere lengths for NCI-275 (A) Lymphocyte telomere lengths for 
members of family NCI-275. Telomere lengths from the proband (indicated with 
x), healthy older sisters (indicated with square), healthy twin sisters (indicated with 
circle), mother (indicated with diamond) and father (indicated with triangle) were 
measured by flow cytometry with fluorescent in situ hybridization. (B) Telomere-
FISH of EBV-transformed lymphoblasts derived from proband and his healthy twin 
sister. Green punctuate staining indicates telomeres. 
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Figure 2.5: The effect of K170Δ on the interaction of TPP1 and telomerase. The 
comparison of TERT pull down by K170Δ TPP1-FLAG versus wild-type TPP1-FLAG 
in the presence of a5 primer. Immunoblot using an anti- TERT or HRP-conjugated 
anti-FLAG antibody of lysates from HeLa cells transfected with FLAG-TPP1, hTERT 
and POT1-FLAG (INPUT).  Immunoblot using an anti- TERT or HRP-conjugated anti-
FLAG antibody of lysates from HeLa cells transfected with FLAG-TPP1 after 
immunoprecipitation using Anti-Flag/M2 affinity gel beads (FLAG IP). The ratio of 
TERT to TPP1-FLAG is normalized against the ratio of TERT to TPP1-FLAG in wild 
type. 
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Figure 2.6: TPP1-K170Δ fails to recruit telomerase to telomeres. (A) Data is 
shown for FISH to detect TR (red) and IF to detect indicated FLAG-TPP1 proteins 
(green) and coilin (Cajal body marker; blue) for the indicated transfections. Merge: 
White (green + blue + red) spots indicate recruitment of telomerase to telomeres to 
foci referred to as neo-Cajal bodies. Purple (blue + red) spots indicate telomerase 
not recruited to telomeres, but rather residing in Cajal bodies. (B) Quantification of 
telomerase recruitment data of which panel A is representative. The average “% 
FLAG-TPP1 foci that contain TR” and standard deviations (error bars) were plotted 
for the indicated transfections. Two-tailed Student t-test with respect to wild-type was 
used to calculate the P-value for K170Δ. 
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Figure 2.7: TPP1 proteins localize at telomeres. Indirect immunofluorescence of 
HeLa cells transfected with indicated FLAG-tagged TPP1 constructs and stained with 
anti-Rap1 and anti-FLAG antibodies.Rap1 is used as telomere marker. 
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Figure 2.8: TPP1-Q205R does not have a significant effect on the recruitment 
of telomerase to telomeres. (A) Data is shown for FISH to detect TR (red) and IF 
to detect indicated FLAG-TPP1 Q205R (green) and coilin (Cajal body marker; 
blue) for the indicated transfections. Merge: White (green + blue + red) spots 
indicate recruitment of telomerase to telomeres to foci referred to as neo-Cajal 
bodies. (B) Quantification of telomerase recruitment data of which panel A is 
representative. The average “% FLAG-TPP1 foci that contain TR” and standard 
deviations (error bars) were plotted for the indicated transfections.  
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Figure 2.9: TPP1-K170Δ is defective in stimulating telomerase enzymatic 
processivity. (A) Direct telomerase primer extension assays using lysates from 
HeLa cells cotransfected with a TR, TERT, and POT1 and the indicated TPP1 
plasmids. The number of (hexameric) telomeric repeats added by telomerase is 
indicated at the left. The region of the gel representing bands indicative of high 
processivity is indicated by a vertical bar at the left. (B) Direct telomerase primer 
extension assays using lysates from HEK293T cells supplemented with 500 nM 
POT1 and the indicated TPP1-N proteins (500 nM each). (C) Quantitation of 
processivity from three independent sets of experiments of which A is representative; 
mean values and standard deviations (error bars) were plotted. (D) Immunoblot of 
lysates used in A probed with anti-Flag antibody– HRP conjugate showing uniform 
TPP1, TERT, and POT1 protein expression. (E) Quantitation of processivity from 
three independent sets of experiments of which B is representative. (F) Coomassie-
stained SDS-PAGE of 4 mg each of the indicated TPP1-N proteins. 
.  
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Figure 2.10: TPP1-P491T stimulates telomerase enzymatic processivity.  
Telomerase activity assay showing stimulation of telomerase processivity by 
wild-type as well as P491T-TPP1 compared to the ‘no POT1-TPP1’ control. 
Direct telomerase primer extension assays using lysates from cells co-
transfected with a TR, TERT, POT1 and indicated TPP1 plasmids. “No POT1-
TPP1” indicates a transfection without POT1 and TPP1. The number of 
(hexameric) telomeric repeats added by telomerase is indicated on the left. The 
region of the gel representing bands indicative of high processivity (>15 
repeats added) is indicated with a vertical bar on the left.  
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Figure 2.11: Effect of P491T on interaction with telomeres (A) Immunoblot 
using an HRP-conjugated anti-FLAG antibody of lysates from HeLa cells 
transfected with FLAG-TPP1 and FLAG TIN2 either before immunoprecipitation 
(INPUT), or after immunoprecipitation using an antibody against TIN2 (α-TIN2 IP). 
(B) The Ratio of the FLAG signal for TPP1 versus TIN2 normalized against wild-
type TPP1/TIN2 was calculated for four independent experiments, and the mean 
values and strandard deviations (error bars) were plotted. Two-tailed Student t-test 
with respect to K170Δ was used to calculate the P-value for P491T. (C) Telomere 
ChIP was conducted with HeLa 1.2.11 cells transfected with plasmids encoding 
either TPP1 (wild-type) or TPP1-P491T and immunoprecipitated with antibodies 
against indicated proteins. The associated DNA was visualized with Southern 
blotting using either with a 32P-labeled telomeric probe or a probe that recognizes 
Alu repeats. (D) Quantitation of data from two experiments of which panel C is 
representative. Mean values and standard errors of the mean (error bars) were 
plotted. 
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Figure 2.12: Structural modeling of TPP1 mutations in TPP1-OB domain.  
Ribbon view of wild-type TPP1-OB crystal structure was used to model (A) ΔK170 
and (B) Q205R structures. Superposition of each mutant with wild-type structure is 
shown in Merge. Note how in the absence of K170 in the model, the E169 side 
chain flips towards the core of the protein in contrast to its surface-exposed 
conformation in the wild-type structure. On the other hand, Q205R in the model 
does not cause a significant change in the structure. 
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Table 2.3: Exome coverage statistics 
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Table 2.4: Exome variant filtering strategy 
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Table 2.5: Rare variants shared by all three short-telomere family members 
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Table 2.6: Primers for ACD locus used in targeted validation sequencing 
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CHAPTER 3: CONCLUSIONS AND DISCUSSION 
TPP1 is one of the components of the shelterin complex, functioning both in end-
protection and telomere length regulation. One major role of TPP1 in telomere length 
maintenance is to recruit telomerase to telomeres. Mutagenesis studies revealed that 
mutations in a specific surface-exposed acidic cluster, called the TEL patch (E168, 
E169, E171, R180, L183, L212, E215), in TPP1 disrupt the recruitment of telomerase to 
telomeres without affecting its end-protection function. In this study, we identified an 
individual with a severe DC variant HH carrying two ACD mutations. One mutation is a 
deletion of K170 (K170Δ), which is located centrally in the TEL patch region between 
E169 and E171; the other one is a missense mutation, P491T, which resides in the 
TIN2-binding domain. The patient is negative for mutations in other DC-associated 
genes.  Considering the role of TPP1 in telomerase recruitment, we hypothesized that 
these mutations in ACD are responsible for HH in this patient. Our goal was to examine 
the functional consequences of the K170Δ and P491T mutations and to determine the 
mechanism by which they cause HH. In chapter 2, we showed that K170Δ compromises 
the recruitment of telomerase to telomeres and significantly reduces the processivity of 
telomerase. On the other hand, P491T did not have a significant effect on the 
recruitment and processivity of telomerase, but it disrupts the interaction between TPP1 
and TIN2. 
K170 resides in the TEL patch of TPP1. Although it is not a surface amino acid, it 
is located adjacent to TEL patch amino acids E168, E169 and E171. To understand the 
effect of the deletion of K170 on the function of TPP1, we addressed three different 
aspects of TPP1 function associated with telomerase that have previously been 
examined for TEL patch mutations [81]. We examined the effect of ΔK170 on direct 
interaction of TPP1 with telomerase using Co-IP experiments (Figure 2.5); we 
monitored recruitment of telomerase to telomeres using IF-FISH experiments (Figure 
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2.6); and we measured enzymatic processivity using telomerase activity assays (Figure 
2.9). Our results demonstrated that ΔK170 compromises the recruitment and 
processivity of telomerase but it has no detectable effect on the interaction between 
TPP1 and telomerase. Our structural model (based on homology modeling) of K170Δ 
dysfunction suggests that deletion of K170 flips E169 into the core of the OB fold 
domain, disabling it from binding to telomerase (Figure 2.12A); hence, compromising 
recruitment and processivity of telomerase. However, since we do not have the crystal 
structure for K170Δ, we cannot rule out the possibility of other disruptive changes 
caused by K170Δ in TPP1. Moreover, the lack of a significant effect of K170Δ on the 
interaction between TPP1 and telomerase suggests that there are different interaction 
points between telomerase and TPP1, which can secure their interaction even when 
one interaction point is lost. Indeed, it has been proposed that two different domains of 
TERT (the CTE and TEN domains) are involved in contacting TPP1, providing support 
for a multi-point telomerase-TPP1 interaction [79]. 
The P491 amino acid is located in the TIN2-binding domain of TPP1. Since its 
location is far from the TEL patch, it is not surprising that P491T has no significant effect 
on telomerase processivity (Figure 2.10) and the recruitment of telomerase to telomeres 
(Figure 2.6). Indeed, consistent with its location, the P491T mutation inhibits the 
interaction between TPP1 and TIN2 (Figure 2.11 A, B).  The physiological consequence 
of this inhibitory effect of P491T is still not clear because it does not seem to be 
affecting TPP1 recruitment to the telomeres in vivo (Figure 2.11 C, D). Although ChIP 
experiments showed that overexpression of P491T does not seem to affect TPP1 
recruitment to telomeres in vivo (Figure 2.11 C, D), we cannot rule out the possibility 
that overexpression of P491T masks the TPP1 recruitment defect. In order to better 
understand the physiological consequence of P491T, using IP experiments, we plan to 
investigate the interaction between TPP1 and TIN2 in EBV-transformed lymphoblastoid 
cells from proband, who carries both P491T and K170Δ, compared to cells from his 
older sister, who carries only K170Δ. Similarly, we can also asses the amount of TPP1 
at telomeres in cells from the proband compared to cells from the older sister via 
telomere ChIP analysis. 
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The P491T variant exists with an allele frequency of 0.000154 in the general 
population, and it is predicted to be probably-damaging/damaging by three computer 
prediction tools (PolyPhen, SIFT, PhastCons). This supports our data showing that 
P491T inhibits the interaction between TPP1 and TIN2. To further understand how 
defects in TPP1-TIN2 interaction can result in telomere dysfunction and disease, it is 
necessary to map the critical amino acid residues of TPP1 that are involved in 
interaction with TIN2; thus, the next step will be to map the TIN2-binding site of TPP1 
using site-directed mutagenesis and/or crystallography. Naturally observed variants, 
such as P491T and several others, can be used as tools to start dissecting the amino 
acid determinants of TPP1-TIN2 interaction. The effect of these mutations/variants on 
the interaction of TPP1-TIN2 will be determined using IP assays. In addition, their effect  
on the recruitment of TPP1 to telomeres will be determined using either telomere ChIP 
or IF-FISH experiments.  
Our data showing that K170Δ, but not P491T, compromises telomerase 
recruitment and processivity are also consistent with telomere lengths of the members 
of the proband`s family. While the family members harboring K170Δ have telomere 
lengths below the first percentile for their age, the others have normal telomere lengths 
(Figure 2.4A). As in the case of other telomere shortening-based diseases, anticipation 
is also seen in the family (from the father to the proband).  Interestingly, the 
heterozygous carriers of K170Δ (the father and the older sister) are clinically unaffected 
at this time, which cannot be explained only by anticipation. The proband, who is the 
only member of family carrying both K170Δ and P491T, is also the only family member 
with HH. On the other hand, the mother, who is a heterozygous carrier of P491T, is 
healthy and has normal telomere lengths. Therefore, we propose that the proband is a 
compound heterozygote and that both K170Δ and P491T contribute to the phenotype of 
the proband, although the contribution of P491T is minor compared to the contribution 
of K170Δ (Figure 3.1). In order to test that, we plan to examine cumulative effect of 
K170Δ and P491T on telomerase recruitment by doing IF-FISH experiments (as in 
figures 2.6 and 2.8) in the presence of both variants. We will also investigate whether 
any of these variants acts in a dominant negative manner by co-expressing each variant 
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with wildtype TPP1 and assessing whether their effect on telomerase recruitment will be 
further impaired. 
While our manuscript reporting this work was in press, Guo et al. identified an 
individual (unrelated to the proband in our study) with aplastic anemia harboring the 
K170Δ mutation [288]. Similar to the family in our study, family members carrying the 
K170Δ mutation in this second family also have short telomeres. Not surprisingly, Guo 
et al. also demonstrated that the K170Δ mutation impairs recruitment of telomerase to 
telomeres [288]. Although this second study did not provide a further link between TPP1 
or telomerase dysfunction with disease, combined with our study, it supports our 
conclusion about the causal relationship between TEL patch mutations and bone 
marrow failure. 
Previously our collaborator, Dr. Sharon Savage, at NCI identified another variant 
in ACD in a different family using a candidate gene strategy, Q205R. Although it is 
located in the OB-fold domain, structural modeling analysis showed that this variant is 
not expected to affect the TEL patch structure. Of note, the patient with the Q205R 
variant was also found to harbor a TER mutation in close vicinity to the RNA templating 
region; hence, this TER mutation is most likely the cause of disease. Moreover, the 
Q205R variant does not have a significant effect on the recruitment of telomerase to 
telomeres (Figure 2.8). Therefore, we hypothesize that Q205R does not contribute to 
DC in this family. Further characterization of Q205R and the TER mutation will provide 
additional information about the precise molecular defects underlying telomere 
shortening in this DC patient. We plan to further investigate the effect of Q205R on 
telomerase processivity and the effect of the TERC mutation on telomerase activity. In 
addition, the crystal structure of TPP1 with the Q205R variant will provide a more 
definitive explanation for the structural effect of the mutation on the TEL patch and on 
the OB domain in general. Based on  our data showing that Q205R does not have an 
effect on the telomerase recruitment function of the TEL patch, we think that we will not 
see a significant structural effect.   
Most of the experiments in our study that involved living cells were performed 
using transient transfections. One of the possible pitfalls of the transient transfections is 
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the overexpression of the protein (i.e TPP1), which may mask possible subtle effects 
caused by the mutations (i.e P491T). Thus, generating stable cell lines expressing the 
patient mutations (as described previously  in Nandakumar et al. 2012) is the next step 
forward in elucidating the effect of the mutations more extensively [81]. Moreover, the 
effect of the mutations on cell proliferation and telomere length cannot be evaluated with 
this method because both of these phenotypes require multiple population doublings to 
evaluate. Thus, stable cell lines will also be utilized to study how the TPP1 mutations 
affect cell proliferation and telomere length in vivo. 
Although DC is characterized by telomere shortening in stem cells due to 
telomerase deficiency, the exact mechanism of pathogenesis is not known for each 
mutation. To understand the pathogenesis of the patient mutations and other TEL patch 
mutations in DC and other bone marrow diseases, it is important to examine their effect 
directly in the bone marrow, particularly in hematopoietic stem cells (HSCs). It has been 
shown that conditional deletion Acd in mice causes rapid loss of HSCs. In the absence 
of TPP1, a massive telomere deprotection phenotype was observed in hematopoietic 
progenitors [286]. Using a similar approach, the effects of the patient mutations and TEL 
patch mutations in both end-protection and telomere length maintenance can be 
elucidated via rescue studies in mice. Since the sequence of the TEL patch is highly 
conserved between mouse and human, the mouse equivalents of the patient and TEL 
patch mutations could be expressed in mouse HSCs. Using conditional deletion of 
endogenous Acd/Tpp1, the effect of the mutations could be examined in HSCs. Since 
mouse telomeres are longer, the role of TEL patch mutations in telomere length 
homeostasis could be studied under high replicative stress to see the possible telomere 
shortening effect more rapidly. 
To understand the mechanisms of diseases, particularly stem cell deficiency 
related diseases, using induced pluripotent stem (iPS) cells derived from patients is 
another relevant strategy. It is known that TERT is reactivated, hence telomerase 
activity is reconstituted in the process of reprogramming [289, 290]. This strategy may 
be sufficient to rescue the phenotype in some DC types; however, it was shown not to 
be successful in the rescue of DC patients with TCAB1 mutations because the defect is 
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in telomerase trafficking rather than telomerase level and activity [214, 291]. It would still 
be interesting to see the extent of the recruitment defect and possible related cell 
proliferation defect in iPS cells from our proband carrying both K170Δ and P491T, the 
heterozygous carriers of K170Δ (the father and the older sister), and the heterozygous 
carrier of P491T (the mother) in this family.  
A recent study showed the value of using genomic-editing technologies to 
engineer TEL patch mutations in hESC [82]. However, mutated hESCs undergo 
senescence; thus, they cannot be used to elucidate the role of the TEL patch in the 
context of complex tissues and organs. Although cell-based studies can provide 
valuable information about the pathogenesis of the patient and TEL patch mutations in 
TPP1, in vivo models will still be tremendously more useful to understand the effect of 
these mutations in different organs and tissues. Therefore, in order to further investigate 
how the patient and TEL patch mutations affect organ development and tissue 
homeostasis,   we are in the process of engineering mice with targeted mutations using 
CRISPR/Cas9. We will investigate the effect of these mutations on mouse development, 
viability and longevity. In particular, we plan to focus on tissues with high cell turn-over 
rate including hair (hair loss or pre-mature greying), skin (change in the thickness of 
epidermis) and bone marrow (HSC depletion). Another advantage of this strategy is that 
we can generate a compound heterozygous mouse to recapitulate the  two mutations 
(K170Δ and P491T) in the proband (from NCI-275 family) and examine whether the 
mouse phenotype correlates with the proband’s severe HH manifestations. 
In the future, there could be a variety of clinical applications of this study.  One of 
the more practical applications would be to use the ACD gene as a diagnostic tool to 
screen for DC. DC patients with no known mutations in 9 DC genes could be screened 
for ACD mutations. Moreover, because cancer cells have to maintain their telomere 
length to avoid senescence/mitotic crisis/apoptosis and telomerase is overexpressed in 
>90% of cancers to ensure telomere length maintenance, targeting telomerase 
recruitment and processivity through the TEL patch will potentially lead to the discovery 
of novel anti-cancer therapeutics. Nakashima et al. showed that a telomerase inhibitor 
(BIBR1532) inhibits proliferation of HeLa cells harboring TEL patch mutations by 
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inducing apoptosis [265]. This observation supports the notion that targeting the TPP1-
telomerase interaction through TEL patch residues with small molecule–based 
therapies will be a useful anticancer therapy approach in telomerase-positive cancer 
cells, especially when it is combined with anti-telomerase therapy. Identification of 
additional causal mutations in DC and other bone marrow failure diseases is also very 
important because in the future, these causative mutations could potentially be 
corrected with one of the several gene-editing methods, such as CRISPR/Cas9 
technology, in bone marrow cells from patients ex vivo. Cells with the corrected gene 
could be transplanted back into the same patient using stem cell transplantation.  
As mentioned before, stem cells depend on telomerase to maintain their 
telomere length in order to sustain their self-renewal capacity. Accordingly, 
understanding the interaction between the TEL patch of TPP1 and telomerase in the 
context of stem cells is extremely valuable because it is the key interaction for 
recruitment of telomerase to the telomere for extension of telomeres. In this study, we 
showed that in a DC patient with extremely short telomeres, the recruitment and 
processivity of telomerase are compromised due a mutation likely affecting the 
structural conformation of the TEL patch. This study provides novel  insights into the 
cause-effect relationship between TEL patch mutations in TPP1 and stem cell 
dysfunction related to telomere shortening in DC. Further studies on TEL patch 
mutations and other patient mutations will provide additional  information regarding  how 
these mutations affect  specific tissues and organs, and thus, the importance of the role 
of the TEL patch for stem cell function in different tissue/organs. 
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Figure 3.1: Potential mechanism underlying the genotype-phenotype relationship 
in family NCI-275. Telomerase recruitment is modestly reduced in the presence of one 
wild type allele and one TPP1-P491T allele, somewhat reduced with one wild type 
allele and one TPP1-K170Δ allele, and significantly reduced with one TPP1-P491T 
allele and one TPP1-K170Δ allele. 
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